Cushing Disease

Somatic MONDO:0009050 Pathograph 11 Show in embeddings browser Cushing's Syndrome

Cushing disease is hypercortisolism caused by a corticotroph adenoma of the anterior pituitary. It is one specific cause of Cushing syndrome, not a synonym for it, and the distinction is mechanistic rather than nosological: here the lesion is above the adrenal, ACTH is high rather than suppressed, and the adrenal cortex is a normal organ responding correctly to an abnormal signal. The tumour's autonomy is what has to be explained, and since 2015 there is a molecular answer for most cases. Somatic variants in USP8, clustered in its 14-3-3 binding motif, release the protease from inhibitory 14-3-3 binding. The cleaved, hyperactive enzyme deubiquitinates EGFR and so rescues it from lysosomal degradation, and the resulting sustained EGF signalling drives POMC transcription. In tumours with wild-type USP8, USP48 and BRAF V600E variants converge on the same POMC promoter from a different direction, and the three are close to mutually exclusive - which is the observation that makes them look like alternative drivers of one pathway rather than incidental passengers. Two things follow clinically. The first is that the disease is defined by a failure of negative feedback: an autonomous corticotroph does not respond to the cortisol it is causing, which is why dexamethasone suppression is both the diagnostic test and a description of the lesion. The second is that the morbidity is not caused by the tumour, which is usually a small benign microadenoma, but by chronic glucocorticoid exposure downstream of it - the cardiovascular, metabolic, skeletal, immune and psychiatric burden that makes this a lethal disease if untreated and that only partly reverses on remission.

Ask OpenScientist

Ask a research question about Cushing Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
6
Pathophys.
14
Phenotypes
1
Gaps
11
Pathograph
4
Genes
4
Medical Actions
3
Subtypes
3
Trials
1
Models
16
References
1
Deep Research
👪

Inheritance

1
Somatic
The driver events are somatic and confined to the tumour. Cushing disease is overwhelmingly sporadic; germline predisposition exists (MEN1, and the familial isolated pituitary adenoma syndromes) but accounts for a small minority and is not modelled here.
◆

Subtypes

3
USP8-mutant corticotroph adenoma
The commonest molecular subgroup. Individual series have reported anything from 35% to 62%, but a meta-analysis of 2,171 cases pools the prevalence at 31.1%, and much of the between-study spread turns out to track the sex ratio of the cohort rather than anything about the tumours. Variants cluster in the 14-3-3 binding motif encoded by exon 14, and are essentially confined to corticotroph adenomas - the same variants are not found in other pituitary adenoma types. The clinical profile is distinctive and internally tensioned: these patients are predominantly female, are diagnosed about four and a half years younger, and are *both* more likely to achieve postoperative remission and more likely to recur.
Show evidence (2 references)
PMID:40392165 SUPPORT Human Clinical
"Pooled prevalence was 31.1% (95% CI, 26.5%-36.0%) and was higher in cases with functional tumours (34.1%; 95% CI, 29.4%-39.1%)."
The pooled prevalence estimate this entry uses in preference to individual-series figures.
PMID:40392165 SUPPORT Human Clinical
"patients with USP8 variant tumours are mostly female, diagnosed at younger age, more likely to achieve postoperative remission, but at a higher risk of recurrence than those with tumours carrying the reference allele"
The clinical associations, including the remission/recurrence pair that this entry treats as being in tension.
USP48-mutant corticotroph adenoma
Recurrent p.M415I or p.M415V variants, found in about 23% of USP8 wild-type corticotroph adenomas. Converges on POMC promoter activation.
BRAF V600E-mutant corticotroph adenoma
BRAF p.V600E in about 16% of USP8 wild-type corticotroph adenomas, acting through MAPK activation onto the same POMC promoter. Of the three drivers this is the one with a directly actionable inhibitor, and primary tumour cells carrying it respond to vemurafenib in vitro.
?

Discussions and Knowledge Gaps

1
Does knowing a corticotroph adenoma's driver genotype change what should be done for the patient?
KNOWLEDGE GAP cd_usp8_status_not_yet_actionable
Attached to
has_subtypes#USP8-mutant treatments#Transsphenoidal Selective Adenomectomy
The molecular subtyping of corticotroph adenomas is now well established - three recurrent drivers, close to mutually exclusive, each converging on POMC - and it has so far changed management for almost nobody. Surgery is offered on the same terms regardless of genotype, and genotype is not routinely determined because the tissue is only available after the operation that would have been done anyway. It is not that the prognostic signal is absent. A meta-analysis of 2,171 cases found USP8-variant tumours significantly more likely to achieve postoperative remission (OR 1.76) and, at the same time, significantly more likely to recur (OR 2.38). Those two point in opposite directions over different time horizons, so USP8 status does not resolve into a single prognostic statement a surgeon can act on at the point of decision - it says this patient is more likely to be in remission next month and more likely to relapse later. Whether that should change follow-up intensity rather than initial management has not been tested, and the pooled data are retrospective and heterogeneous enough that the authors attribute much of the between-study variation to cohort sex ratio. And the pooled signal is contested by the primary literature. The largest single USP8 series reports that recurrence rate and recurrence period were unrelated to USP8 status, and a separate operated cohort analysing recurrence predictors directly found USP8 and USP48 status not associated with recurrence. So the meta-analytic OR of 2.38 is not corroborated by either primary series that looked for it, which is a stronger reason than heterogeneity alone to treat USP8 status as prognostically unsettled. BRAF V600E is the cleaner opportunity and the more specific one. It is directly druggable, primary tumour cells carrying it respond to vemurafenib in vitro, and it accounts for roughly one in six USP8 wild-type tumours. No trial has tested it. The gap is therefore not knowledge of the biology, which is unusually well worked out for a rare endocrine tumour, and no longer quite "no association has been shown" either. It is that no study has linked driver genotype prospectively to a decision a clinician makes.
Proposed experiments
Prospective association of driver genotype with post-surgical remission and recurrence
cd_driver_genotype_vs_surgical_outcome
Genotype resected corticotroph adenomas for USP8, USP48 and BRAF in a prospective surgical cohort and relate driver status to initial remission and to recurrence over long-term follow-up, adjusting for the tumour characteristics already known to predict outcome - invasiveness, size and MRI visibility.
Would support
has_subtypes#USP8-mutant
Supporting outcome
  • Driver genotype predicts remission or recurrence prospectively after adjustment for tumour size, invasiveness and cohort sex ratio, reproducing the direction of the pooled retrospective estimates.
Refuting outcome
  • Genotype adds nothing once size, invasiveness and sex are accounted for, meaning the pooled association is confounded by the cohort composition the meta-regression already implicated.
Show evidence (3 references)
PMID:40392165 SUPPORT Human Clinical
"USP8 status was associated with higher odds for postoperative remission (OR 1.76, 95% CI, 1.18-2.63) and recurrence (OR 2.38, 95% CI, 1.03-5.48)."
The pooled association this discussion is built around.
PMID:25675982 REFUTE Human Clinical
"the recurrence rate and the average recurrence period were unrelated to the USP8 mutational status"
A primary series disagreeing with the pooled recurrence estimate.
PMID:40257708 REFUTE Human Clinical
"Age, gender, tumor diameter, USP8 and USP48 mutational status, cortisol on the 7th post-operative day and, ACTH immuno-positivity in histology were not associated with recurrence."
A second, independent operated cohort that looked directly for a genotype-recurrence association and did not find one.
⚙

Pathophysiology

6
Somatic Driver Mutation in the Corticotroph
A somatic variant arises in a single anterior pituitary corticotroph and gives it a growth and secretory advantage. USP8 is the commonest driver, with variants clustering in the 14-3-3 protein binding motif rather than being distributed across the gene - a positional pattern that signals a gain-of-function mechanism rather than loss of the protease. In USP8 wild-type tumours the drivers are USP48 (p.M415I/p.M415V) and BRAF p.V600E. The three are close to mutually exclusive across a 169-tumour series, which is the evidence that they are alternative entries into one pathway. Loss-of-function variants in NR3C1, the glucocorticoid receptor, appear in a minority and attack the same autonomy from the feedback side.
corticotroph CL:0002309 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves corticotroph (CL:0002309). CL:0002309 is a cell type from the Cell Ontology.
Genetic context USP8 hgnc:12631 HUGO Gene Nomenclature Committee (hgnc) Relation: this genetic context concerns this gene This genetic context concerns USP8 (hgnc:12631). hgnc:12631 is a gene from the HUGO Gene Nomenclature Committee. variant_origin: SOMATIC functional_impact_category: GAIN_OF_FUNCTION
protein deubiquitination GO:0016579 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased protein deubiquitination (GO:0016579). GO:0016579 is a biological process from the Gene Ontology. ↑ INCREASED
cysteine-type deubiquitinase activity GO:0004843 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves cysteine-type deubiquitinase activity (GO:0004843), qualified as gain of function. GO:0004843 is a molecular function from the Gene Ontology. ⇑ GAIN OF FUNCTION
adenohypophysis UBERON:0002196 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in adenohypophysis (UBERON:0002196). UBERON:0002196 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Sustained EGFR Signalling
Show evidence (4 references)
PMID:25485838 SUPPORT Human Clinical
"We found somatic mutations in the USP8 deubiquitinase gene in 4 of 10 adenomas. The mutations clustered in the 14-3-3 protein binding motif and enhanced the proteolytic cleavage and catalytic activity of USP8."
Establishes the somatic USP8 driver and the positional clustering that indicates gain rather than loss of function.
PMID:25675982 SUPPORT Human Clinical
"Targeted sequencing further identified a total of 17 types of USP8 variants in 67 of 108 ACTH-secreting PAs (62.04%). However, none of these mutations was detected in other types of PAs (n = 150)."
Gives the mutation frequency and the specificity to corticotroph adenomas, which is what makes USP8 a disease-defining driver rather than a general pituitary tumour event.
PMID:30093687 SUPPORT Human Clinical
"we report recurrent mutations in the deubiquitinase gene USP48 (predominantly encoding p.M415I or p.M415V; 21/91 subjects) and BRAF (encoding p.V600E; 15/91 subjects) in corticotroph adenomas with wild-type USP8"
Identifies the two drivers that account for a substantial share of USP8 wild-type tumours.
+ 1 more reference
Sustained EGFR Signalling
Wild-type USP8 is held inactive by 14-3-3 binding. Variants in that motif disrupt the interaction, allowing proteolytic cleavage into a hyperactive fragment which deubiquitinates EGFR. Ubiquitination is the signal that routes an activated receptor to the lysosome, so removing it rescues EGFR from degradation and returns it to the surface. The corticotroph therefore experiences continuous EGF pathway signalling from a normal amount of ligand - the defect is in receptor disposal, not in ligand supply. BRAF V600E reaches the same downstream state by constitutively activating the MAPK cascade below the receptor.
corticotroph CL:0002309 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves corticotroph (CL:0002309). CL:0002309 is a cell type from the Cell Ontology.
epidermal growth factor receptor signaling pathway GO:0007173 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves epidermal growth factor receptor signaling pathway (GO:0007173), qualified as gain of function. GO:0007173 is a biological process from the Gene Ontology. ⇑ GAIN OF FUNCTION ERK1 and ERK2 cascade GO:0070371 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased ERK1 and ERK2 cascade (GO:0070371). GO:0070371 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
POMC Transcription and ACTH Hypersecretion
Show evidence (3 references)
PMID:25485838 SUPPORT In Vitro
"Cleavage of USP8 led to increased deubiqutination of the EGF receptor, impairing its downregulation and sustaining EGF signaling."
The mechanistic step from the mutant protease to sustained receptor signalling. (The spelling of "deubiqutination" is as published.)
PMID:25675982 SUPPORT In Vitro
"These mutations aggregate within the 14-3-3 binding motif of USP8 and disrupt the interaction between USP8 and 14-3-3 protein, resulting in an elevated capacity to protect EGFR from lysosomal degradation."
Names the specific regulatory interaction lost and the trafficking consequence.
PMID:30093687 SUPPORT In Vitro
"BRAF V600E results in constitutive activation of the BRAF kinase activity and its downstream MAPK pathway"
Establishes the alternative route into the same signalling state in BRAF-mutant tumours.
POMC Transcription and ACTH Hypersecretion
Proopiomelanocortin is the precursor from which ACTH is cleaved, so POMC promoter activity sets corticotroph output. All three drivers increase it. This convergence is the strongest argument that the molecular heterogeneity of these tumours is superficial: whatever the driver, the phenotype is excess ACTH, and the tumours are otherwise clinically indistinguishable.
corticotroph CL:0002309 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves corticotroph (CL:0002309). CL:0002309 is a cell type from the Cell Ontology.
corticotropin secretion GO:0051458 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased corticotropin secretion (GO:0051458). GO:0051458 is a biological process from the Gene Ontology. ↑ INCREASED
Experimental models
AtT-20 murine corticotroph tumour cell line CELL LINE Reproduces regulated POMC transcription and ACTH secretion in a corticotroph tumour cell, which is the node this entry treats as the convergence point of all three drivers.
Downstream
Loss of Glucocorticoid Negative Feedback
Adrenocortical Stimulation and Cortisol Excess
Show evidence (2 references)
PMID:25485838 SUPPORT In Vitro
"USP8 mutants enhanced promoter activity of the gene encoding proopiomelanocortin."
Direct demonstration that the USP8 driver acts on POMC transcription.
PMID:30093687 SUPPORT In Vitro
"Similar to USP8 mutants, both USP48 and BRAF mutants enhance the promoter activity and transcription of the gene encoding proopiomelanocortin (POMC), which is the precursor of ACTH, providing a potential mechanism for ACTH overproduction in corticotroph adenomas."
The convergence of all three drivers on the same transcriptional output.
Loss of Glucocorticoid Negative Feedback
A normal corticotroph suppresses ACTH when circulating cortisol rises. The adenoma does not, so the axis stabilises at a pathologically high setpoint with both ACTH and cortisol elevated - the combination that distinguishes this from adrenal Cushing syndrome, where ACTH is suppressed. The relative resistance is graded rather than absolute, which is what allows the high-dose dexamethasone test to separate pituitary from ectopic ACTH sources. In a minority of tumours the feedback lesion is direct, through loss-of-function variants in the glucocorticoid receptor gene itself.
corticotropin secretion GO:0051458 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves corticotropin secretion (GO:0051458), qualified as gain of function. GO:0051458 is a biological process from the Gene Ontology. ⇑ GAIN OF FUNCTION
Downstream
Adrenocortical Stimulation and Cortisol Excess
Show evidence (2 references)
PMID:30093687 SUPPORT Human Clinical
"loss-of-function mutations of the glucocorticoid receptor gene NR3C1"
Identifies the receptor whose loss removes feedback directly, in the minority of tumours carrying such variants.
PMID:26156970 SUPPORT Human Clinical
"The 1 mg overnight dexamethasone suppression test interrogates whether glucocorticoid negative feedback is normal."
States that the standard screening test is a direct probe of the feedback lesion described by this node.
Adrenocortical Stimulation and Cortisol Excess
Chronically elevated ACTH drives bilateral adrenocortical hyperplasia and sustained cortisol output. The adrenal is not diseased here - it is responding normally to an abnormal signal, which is why removing the pituitary source restores adrenal behaviour and why bilateral adrenalectomy works as a last-resort treatment despite doing nothing about the tumour.
glucocorticoid secretion GO:0035933 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased glucocorticoid secretion (GO:0035933). GO:0035933 is a biological process from the Gene Ontology. ↑ INCREASED cortisol biosynthetic process GO:0034651 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cortisol biosynthetic process (GO:0034651). GO:0034651 is a biological process from the Gene Ontology. ↑ INCREASED
adrenal cortex UBERON:0001235 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in adrenal cortex (UBERON:0001235). UBERON:0001235 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Systemic Glucocorticoid Toxicity
Show evidence (1 reference)
PMID:30093687 SUPPORT Human Clinical
"Chronic elevation of ACTH stimulates the adrenal glands to secrete excessive glucocorticoids, which subsequently induces hypercortisolism"
States the ACTH-to-adrenal step explicitly.
Systemic Glucocorticoid Toxicity
Every clinically important consequence of Cushing disease sits at this node rather than at the tumour. Chronic cortisol excess produces central adiposity with peripheral wasting, proximal myopathy, dermal atrophy with wide purple striae, insulin resistance and diabetes, hypertension, osteoporosis, hypercoagulability, immunosuppression and mood and cognitive disturbance. The burden is cumulative and outlives the biochemistry: mortality is raised relative to the general population, and quality of life after remission does not fully normalise.
Show evidence (2 references)
PMID:26156970 SUPPORT Human Clinical
"In addition to classical features of glucocorticoid excess, such as proximal muscle weakness and wide purple striae, patients may present with the associated comorbidities that are caused by hypercortisolism. These include cardiovascular disease, thromboembolic disease, psychiatric and cognitive..."
Enumerates the multisystem toxicity attributed directly to the cortisol excess.
PMID:26156970 SUPPORT Human Clinical
"Endogenous pathologic hypercortisolism, or Cushing's syndrome, is associated with poor quality of life, morbidity, and increased mortality."
Establishes that the outcome burden is attributable to the hypercortisolism itself.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Cushing Disease Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

14
Blood 1
Easy Bruising FREQUENT Bruising susceptibility HP:0000978 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bruising susceptibility (HP:0000978). HP:0000978 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:26156970 SUPPORT Human Clinical
"Easy bruising and osteoporosis were more common in patients with Cushing's syndrome"
Reports easy bruising as discriminating for Cushing syndrome in a comparative study.
Cardiovascular 1
Hypertension FREQUENT HP:0000822 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypertension (HP:0000822). HP:0000822 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:26156970 SUPPORT Human Clinical
"most of the signs and symptoms of Cushing's syndrome are common in the general population (e.g., hypertension and weight gain) and not all are present in every patient"
PARTIAL because the source names hypertension as a feature while making the point that it is non-specific, which is the correct strength for this claim rather than a frequency estimate.
PMID:42572239 SUPPORT Human Clinical
"the recorded burden of cardiometabolic comorbidities at tertiary-care assessment, including hypertension (70.8%) and diabetes mellitus (48.0%), was higher in older age groups"
Supplies a counted frequency (70.8%) in a 277-patient Cushing disease cohort, which the earlier non-specificity snippet did not.
Endocrine 1
Diabetes Mellitus FREQUENT HP:0000819 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Diabetes mellitus (HP:0000819). HP:0000819 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:26156970 SUPPORT Human Clinical
"the frequency of many features of Cushing's syndrome were similar in both groups, including diabetes, hypertension, acne, hirsutism and menstrual disorders"
PARTIAL because the source establishes diabetes as a recognised feature while explicitly reporting that it did not discriminate Cushing syndrome from pseudo-Cushing states.
PMID:42572239 SUPPORT Human Clinical
"the recorded burden of cardiometabolic comorbidities at tertiary-care assessment, including hypertension (70.8%) and diabetes mellitus (48.0%), was higher in older age groups"
Supplies the counted diabetes frequency (48.0%) in a Cushing disease cohort rather than the pseudo-Cushing comparison used previously.
Genitourinary 1
Menstrual Irregularity FREQUENT Irregular menstruation HP:0000858 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Irregular menstruation (HP:0000858). HP:0000858 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:42572239 SUPPORT Human Clinical
"Younger patients showed a relatively higher recorded frequency of dermatological and reproductive manifestations, including striae, acne, and menstrual irregularities"
Reports menstrual irregularity among the reproductive manifestations, and its age distribution.
Immune 1
Susceptibility to Infection OCCASIONAL Recurrent infections HP:0002719 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Recurrent infections (HP:0002719). HP:0002719 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:26156970 SUPPORT Human Clinical
"These include cardiovascular disease, thromboembolic disease, psychiatric and cognitive deficits, and infections."
Lists infection among the comorbidities caused by hypercortisolism.
PMID:30715394 SUPPORT Human Clinical
"Excess mortality was also found associated with infections and suicide."
Establishes infection as a contributor to the excess mortality, which is why this is modelled rather than left in prose.
Integument 2
Wide Purple Striae FREQUENT Striae distensae HP:0001065 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Striae distensae (HP:0001065). HP:0001065 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:26156970 SUPPORT Human Clinical
"proximal muscle weakness, wasting of the extremities with increased fat in the abdomen, torso and face, and wide purple striae, suggest marked hypercortisolism"
Names wide purple striae among the discriminating features of marked hypercortisolism.
Hyperpigmentation FREQUENT Hyperpigmentation of the skin HP:0000953 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hyperpigmentation of the skin (HP:0000953). HP:0000953 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:42572239 SUPPORT Human Clinical
"Classical cushingoid features were highly prevalent, including weight gain (79.4%), centripetal obesity (62.5%), hyperpigmentation (61.0%), and proximal myopathy (60.6%)."
The counted frequency of hyperpigmentation in a 277-patient Cushing disease cohort.
Musculoskeletal 2
Proximal Myopathy FREQUENT Proximal muscle weakness HP:0003701 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Proximal muscle weakness (HP:0003701). HP:0003701 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:26156970 SUPPORT Human Clinical
"classical features of glucocorticoid excess, such as proximal muscle weakness and wide purple striae"
Identifies proximal muscle weakness as a classical feature of glucocorticoid excess.
PMID:42572239 SUPPORT Human Clinical
"Classical cushingoid features were highly prevalent, including weight gain (79.4%), centripetal obesity (62.5%), hyperpigmentation (61.0%), and proximal myopathy (60.6%)."
Counted frequency for proximal myopathy (60.6%).
Osteoporosis FREQUENT HP:0000939 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Osteoporosis (HP:0000939). HP:0000939 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:26156970 SUPPORT Human Clinical
"Easy bruising and osteoporosis were more common in patients with Cushing's syndrome"
Reports osteoporosis as discriminating Cushing syndrome from pseudo-Cushing states in a comparative study.
Nervous System 1
Mood and Cognitive Disturbance FREQUENT Depression HP:0000716 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Depression (HP:0000716). HP:0000716 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:26156970 SUPPORT Human Clinical
"Mood and cognitive changes have long been recognized as important clues to the presence of Cushing's syndrome"
Establishes the neuropsychiatric component as a recognised part of the syndrome.
Growth 1
Central Obesity VERY_FREQUENT Truncal obesity HP:0001956 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Truncal obesity (HP:0001956). HP:0001956 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:26156970 SUPPORT Human Clinical
"wasting of the extremities with increased fat in the abdomen, torso and face"
Describes the truncal redistribution of fat with peripheral wasting.
PMID:42572239 SUPPORT Human Clinical
"Classical cushingoid features were highly prevalent, including weight gain (79.4%), centripetal obesity (62.5%), hyperpigmentation (61.0%), and proximal myopathy (60.6%)."
Counted frequency for centripetal obesity in a 277-patient cohort.
Other 3
Elevated Circulating Cortisol VERY_FREQUENT Increased circulating cortisol level HP:0003118 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Increased circulating cortisol level (HP:0003118). HP:0003118 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:26156970 SUPPORT Human Clinical
"Patients with Cushing's syndrome lose this diurnal nadir and have increased serum and salivary cortisol values at bedtime compared with obese and pseudo-Cushing's patients"
Documents both the elevation and the loss of circadian rhythm that defines it.
Elevated Circulating ACTH VERY_FREQUENT Increased circulating ACTH level HP:0003154 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Increased circulating ACTH level (HP:0003154). HP:0003154 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:25675982 SUPPORT Human Clinical
"Cushing's disease, also known as adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas (PAs) that cause excess cortisol production"
States the ACTH-secreting character of the tumour that produces this phenotype.
Hypercoagulability and Venous Thromboembolism OCCASIONAL Venous thrombosis HP:0004936 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Venous thrombosis (HP:0004936). HP:0004936 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:39182834 SUPPORT Human Clinical
"Pooled postoperative VTE incidence in patients undergoing transsphenoidal surgery for CD was 2% (58 out of 2997)."
The pooled postoperative VTE rate quoted here.
PMID:39182834 SUPPORT Human Clinical
"highlighting that surgical resection of the corticotroph adenoma does not necessarily result in immediate resolution of hypercoagulability"
Supports the statement that the thrombotic risk window outlasts the operation.
🧬

Genetic Associations

4
USP8
Gene: USP8 hgnc:12631 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is USP8 (hgnc:12631). hgnc:12631 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (1 reference)
PMID:25485838 SUPPORT Human Clinical
"our data show that dominant mutations in USP8 cause Cushing's disease via activation of EGF receptor signaling"
The causal conclusion of the discovery study.
USP48
Gene: USP48 hgnc:18533 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is USP48 (hgnc:18533). hgnc:18533 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (1 reference)
PMID:30093687 SUPPORT Human Clinical
"Combining the data from whole-exome and targeted sequencing, which included a total of 91 samples, we found that 16.5% of the cases (15/91) had BRAF V600E mutations and 23.1% of the cases (21/91) harbored USP48 mutations."
Gives the USP48 mutation frequency among USP8 wild-type corticotroph adenomas - 23.1% of 91 cases - alongside the BRAF figure from the same combined analysis.
BRAF
Gene: BRAF hgnc:1097 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is BRAF (hgnc:1097). hgnc:1097 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (1 reference)
PMID:30093687 SUPPORT In Vitro
"primary corticotroph tumor cells harboring BRAF V600E are sensitive to the BRAF inhibitor vemurafenib"
The result that makes BRAF status therapeutically relevant.
NR3C1
Gene: NR3C1 hgnc:7978 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is NR3C1 (hgnc:7978). hgnc:7978 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: MODIFIER
Show evidence (1 reference)
PMID:30093687 SUPPORT Human Clinical
"loss-of-function mutations of the glucocorticoid receptor gene NR3C1"
PARTIAL because the source identifies NR3C1 among candidate lesions in a small number of tumours rather than establishing it as a recurrent driver on the scale of the other three. The source describes NR3C1 as a critical negative regulator of ACTH production, but that phrase is interrupted by inline citation markers in the cached text and so is not quoted here.
💊

Medical Actions

4
Transsphenoidal Selective Adenomectomy
Action: surgical procedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is surgical procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
First-line treatment and the only one that addresses the lesion itself. Reported initial remission in a 1106-patient single-centre series was 72.5%, with about a quarter left in persistent hypercortisolism. Remission is substantially lower with invasive tumours, macroadenomas, pathologically negative specimens and repeat surgery, so the figure quoted for any given patient depends on which of those apply. Remission is not the end of the story: recurrence occurred in 27.4% of patients over a median 38 months in one operated series, and is markedly higher after macroadenoma resection than after microadenoma or no visible lesion (45% versus 19%). An early postoperative nadir cortisol at or below 3 mcg/dL is the best available predictor of durable remission.
Mechanism Target:
INHIBITS POMC Transcription and ACTH Hypersecretion — Removes the autonomous ACTH source, which is why it is the only treatment that can restore a normal axis rather than manage its output.
Show evidence (4 references)
PMID:34415482 SUPPORT Human Clinical
"After surgery, the overall postoperative initial remission rate was 72.5, and 27.5% of patients maintained persistent hypercortisolism."
The remission rate this entry reports, from the largest single-centre series available.
PMID:34415482 SUPPORT Human Clinical
"preoperative invasiveness based on MRI, intraoperative invasiveness, macroadenomas pathologically negative, and repeat TSS are related to lower initial remission rates"
The determinants that qualify the headline remission figure.
PMID:40257708 SUPPORT Human Clinical
"Surgical remission was achieved in 81% of patients, but recurrence occurred in 27.4% of cases after a median follow up period of 38 months (range 16-101)."
The recurrence rate, which this entry now reports alongside remission because Cushing disease is a relapsing condition.
+ 1 more reference
Osilodrostat
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: osilodrostat CHEBI:755118 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses osilodrostat (CHEBI:755118). CHEBI:755118 is a therapeutic agent from Chemical Entities of Biological Interest.
An oral 11-beta-hydroxylase inhibitor that blocks the final step of cortisol synthesis in the adrenal. It treats the consequence rather than the cause - the tumour is untouched and ACTH typically rises - which is also why hypocortisolism and accumulation of adrenal steroid precursors are the characteristic adverse effects rather than incidental ones. A second Phase III trial, LINC 4, tested it against placebo from the outset rather than in a withdrawal design and found 77% versus 8% achieving normal urinary free cortisol at 12 weeks - so the effect is not an artefact of the LINC 3 withdrawal structure.
Mechanism Target:
INHIBITS Adrenocortical Stimulation and Cortisol Excess — Inhibits adrenal steroidogenesis downstream of ACTH, lowering cortisol without altering the pituitary lesion.
Show evidence (3 references)
PMID:32730798 SUPPORT Human Clinical
"More patients maintained a complete response with osilodrostat versus with placebo at week 34 (31 [86%] vs ten [29%]; odds ratio 13·7 [95% CI 3·7-53·4]; p<0·0001)."
The randomised withdrawal result establishing efficacy against placebo.
PMID:32730798 SUPPORT Human Clinical
"Hypocortisolism occurred in 70 (51%) patients and adverse events related to adrenal hormone precursors occurred in 58 (42%) patients."
The adverse-effect profile that follows mechanistically from blocking the final synthetic step.
PMID:35325149 SUPPORT Human Clinical
"At week 12, significantly more osilodrostat (77%) than placebo (8%) patients achieved mUFC ≤ ULN (odds ratio 43.4; 95% CI 7.1, 343.2; P < 0.0001)."
The LINC 4 placebo-controlled result, which corroborates LINC 3 with a different trial design.
Pasireotide
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: pasireotide CHEBI:72312 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses pasireotide (CHEBI:72312). CHEBI:72312 is a therapeutic agent from Chemical Entities of Biological Interest.
A multi-receptor somatostatin analogue with affinity for SSTR5, which corticotroph adenomas express. Unlike osilodrostat it acts on the tumour rather than the adrenal. In the long-acting Phase III extension, urinary free cortisol was at or below the upper limit of normal in about half of patients at last assessment and clinical improvements were sustained. The cost is metabolic and predictable rather than idiosyncratic: SSTR5 agonism impairs insulin secretion, and hyperglycaemia-related adverse events occurred in 39.5% of patients.
Mechanism Target:
INHIBITS POMC Transcription and ACTH Hypersecretion — Suppresses ACTH secretion from the adenoma through somatostatin receptor agonism.
Show evidence (3 references)
PMID:31465533 SUPPORT Human Clinical
"mUFC was ≤ULN in 42/81 (51.9%), 13/81 (16.0%) and 43/81 (53.1%) patients at extension baseline, month (M) 36 and last assessment."
The biochemical response rates from the long-acting pasireotide Phase III extension.
PMID:31465533 SUPPORT Human Clinical
"Long-acting pasireotide provided sustained biochemical and clinical improvements, with no new safety signals emerging, supporting its use as an effective long-term therapy for CD."
The study's conclusion on sustained efficacy.
PMID:31465533 SUPPORT Human Clinical
"Hyperglycaemia-related AEs occurred in 39.5% of patients."
The class effect that follows from SSTR5 agonism impairing insulin secretion.
Bilateral Adrenalectomy
Action: adrenalectomyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is adrenalectomy (NCIT:C15177). NCIT:C15177 is a clinical intervention from the NCI Thesaurus. Ontology label: Adrenalectomy NCIT:C15177
Definitive control of hypercortisolism for refractory disease, at the cost of permanent adrenal insufficiency and the risk of Nelson syndrome as the unresected corticotroph tumour loses what feedback restraint it had. It cures the cortisol excess while leaving the actual lesion in place, which is an unusually clear illustration of where in this pathograph the morbidity sits.
Mechanism Target:
INHIBITS Adrenocortical Stimulation and Cortisol Excess — Removes the effector organ, abolishing cortisol output regardless of ACTH.
Show evidence (1 reference)
PMID:34687601 SUPPORT Human Clinical
"Cushing's disease requires accurate diagnosis, careful treatment selection, and long-term management to optimise patient outcomes."
PARTIAL because the abstract establishes that treatment selection is the subject of consensus recommendation without stating an adrenalectomy-specific outcome. The specific claims in this entry's description are not carried by this snippet.
🔬

Biochemical Markers

1
Early postoperative nadir serum cortisol
Show evidence (1 reference)
PMID:40257708 SUPPORT Human Clinical
"Nadir cortisol concentrations ≤3 mcg/dL during the first post-operative week predicted long-term remission with 74% sensitivity, 85% specificity, 94% positive predictive value, and 50% negative predictive value (area under the curve 0.808, p = 0.001)."
The full operating characteristics, including the asymmetry between positive and negative predictive value that this entry flags.
🔬

Diagnosis

2
Screening for Hypercortisolism
Two of three tests are used to establish endogenous hypercortisolism before the cause is pursued: 24-hour urine free cortisol, late-night salivary cortisol, and the 1 mg overnight dexamethasone suppression test. Exogenous glucocorticoid use has to be excluded first, and each test has a documented false-positive profile - oral oestrogens raise cortisol-binding globulin, CYP3A4-interacting drugs alter dexamethasone clearance, and the pseudo-Cushing states raise urine free cortisol physiologically.
laboratory procedure NCIT:C25294 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:26156970 SUPPORT Human Clinical
"The guideline recommends using two of three screening tests to establish the diagnosis: UFC, late night salivary cortisol or 1mg dexamethasone suppression test"
States the recommended screening strategy this entry describes.
Pituitary MRI and Inferior Petrosal Sinus Sampling
Once ACTH-dependent hypercortisolism is established, the question is whether the source is pituitary or ectopic. MRI finds the adenoma in most but not all cases - a substantial minority are MRI-negative, and those patients have measurably lower surgical remission rates, which is why petrosal sinus sampling retains a role.
magnetic resonance imaging procedure NCIT:C16809 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:34415482 SUPPORT Human Clinical
"The initial remission rate in patients with pseudocapsule-based extracapsular resection (88.1%), MRI-visible adenoma (74.2%) was higher than that in patients without pseudocapsule-based extracapsular resection (77.1%), and with MRI-negative results (64.5%)"
Quantifies the outcome difference between MRI-visible and MRI-negative disease that motivates further localisation.
📊

Prevalence

1
Sweden
Annual Incidence 0.16 per 100,000 (0.14–0.18) 1–9 per 1,000,000
1.6 cases per million per year (95% CI 1.4-1.8), normalised to 0.16 per 100,000. From a nationwide registry cohort in which every diagnosis was validated against clinical, biochemical, imaging and histopathological data - which matters here, because only 41% of the 1,317 patients carrying a Cushing diagnostic code turned out to have confirmed Cushing disease. An unvalidated code-based count would overstate this figure roughly 2.5-fold.
Show evidence (2 references)
PMID:30799512 SUPPORT Human Clinical
"The mean (95% confidence interval) annual incidence between 1987 and 2013 of confirmed CD was 1.6 (1.4-1.8) cases per million."
The validated nationwide incidence estimate this record normalises.
PMID:30799512 SUPPORT Human Clinical
"Of 1317 patients identified, 534 (41%) had confirmed CD."
The validation yield, which is why this entry prefers this figure over a code-based or secondarily cited one.
⚖️

Clinical Burden

High
Cushing disease roughly doubles mortality. In an unselected Swedish nationwide cohort of 502 patients the standardised mortality ratio was 2.5, with cardiovascular death the commonest cause and excess mortality also from infection and suicide. Crucially the excess does not disappear on cure: for patients in remission the SMR was still 1.9. That residual is the strongest argument in this entry for treating the accumulated glucocorticoid damage, rather than the tumour, as the thing that determines outcome.
Show evidence (2 references)
PMID:30715394 SUPPORT Human Clinical
"The observed number of deaths was 133 vs 54 expected, resulting in an overall SMR of 2.5 (95% CI, 2.1 to 2.9). The commonest cause of death was cardiovascular diseases (SMR, 3.3; 95% CI, 2.6 to 4.3)."
The nationwide mortality estimate and its leading cause.
PMID:30715394 SUPPORT Human Clinical
"For patients in remission, the SMR was 1.9 (95% CI, 1.5 to 2.3)"
The residual excess mortality after remission, which this entry treats as the key burden finding.
🔬

Clinical Trials

3
NCT02180217 PHASE_III COMPLETED
LINC 3. Open-label osilodrostat titration followed by a double-blind randomised withdrawal period - the design that isolates the drug effect from spontaneous fluctuation in a disease with variable cortisol output.
Target Phenotypes: Increased circulating cortisol level HP:0003118 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Increased circulating cortisol level (HP:0003118). HP:0003118 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT02180217 SUPPORT Human Clinical
"It was a pivotal trial which supported the registration of LCI699 for the treatment of patients with Cushing's disease in the US and the EU."
The registration trial for osilodrostat, whose published results this entry cites as PMID:32730798.
NCT02697734 PHASE_III COMPLETED
LINC 4. Placebo-controlled from the outset for 12 weeks, then open-label to 48 weeks - the design that answers the objection that LINC 3's withdrawal structure could inflate the apparent effect.
Target Phenotypes: Increased circulating cortisol level HP:0003118 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Increased circulating cortisol level (HP:0003118). HP:0003118 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT02697734 SUPPORT Human Clinical
"The purpose of this study was to confirm efficacy and safety of osilodrostat for the treatment of patients with Cushing's disease who are candidates for medical therapy."
The registered objective of LINC 4, whose published results this entry cites as PMID:35325149.
NCT01374906 PHASE_III COMPLETED
The long-acting pasireotide Phase III study and its open-label extension, which supplies this entry's pasireotide efficacy and hyperglycaemia figures.
Target Phenotypes: Increased circulating ACTH level HP:0003154 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Increased circulating ACTH level (HP:0003154). HP:0003154 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT01374906 SUPPORT Human Clinical
"This is a randomized, double-blind, multicenter, phase III study to evaluate the safety and efficacy of 2 dosing regiments of Pasireotide long acting release (LAR) in patients with Cushing's disease."
The registered design of the long-acting pasireotide trial whose extension results this entry cites as PMID:31465533.
🧫

Experimental Models

1
AtT-20 murine corticotroph tumour cell line CELL_LINE
The standard in vitro model for ACTH-secreting tumours, used in culture and as nude-mouse xenografts. Its value is that it couples a measurable ACTH output to POMC transcription, so a candidate that acts on the transcriptional node can be read out directly.
Organism
house mouse NCBITaxon:10090 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in house mouse, annotated with Mus musculus (NCBITaxon:10090). NCBITaxon:10090 is an organism from the NCBI Taxonomy.
Publication
PMID:28505327
Pathograph links
POMC Transcription and ACTH Hypersecretion partially recapitulates fidelity: moderate Reproduces regulated POMC transcription and ACTH secretion in a corticotroph tumour cell, which is the node this entry treats as the convergence point of all three drivers.
Limitations: AtT-20 cells do not carry the human USP8 hotspot variant, and no widely used genetically engineered mouse reproduces USP8-driven Cushing disease. So the line models the output of the pathway without modelling the lesion that drives it - it is informative about POMC/ACTH regulation and uninformative about the driver biology that distinguishes this disease from any other cause of corticotroph ACTH excess.
Readouts
Secreted ACTH
Direction: DECREASED
Interpretation: HDAC inhibition lowers secreted ACTH and POMC transcription together, supporting POMC transcription as the controlling step for ACTH output in this model.
Show evidence (1 reference)
PMID:28505327 SUPPORT In Vitro
"early (3-hour) significant decline (70%; P < 0.0001) of secreted ACTH and diminished POMC transcription was observed with SAHA"
The paired ACTH and POMC measurement behind this readout.
Show evidence (1 reference)
PMID:28505327 SUPPORT In Vitro
"Testing the efficacy of suberoylanilide hydroxamic acid (SAHA) on human and murine ACTH-secreting tumor (AtT-20) cells."
Establishes AtT-20 as the model system used for ACTH-secreting tumour pharmacology, alongside human-derived corticotroph tumour cells.
{ }

Source YAML

click to show 
name: Cushing Disease
creation_date: '2026-08-28T22:05:00Z'
category: Somatic
description: 'Cushing disease is hypercortisolism caused by a corticotroph adenoma of the anterior pituitary.
  It is one specific cause of Cushing syndrome, not a synonym for it, and the distinction is mechanistic rather
  than nosological: here the lesion is above the adrenal, ACTH is high rather than suppressed, and the adrenal
  cortex is a normal organ responding correctly to an abnormal signal.

  The tumour''s autonomy is what has to be explained, and since 2015 there is a molecular answer for most cases.
  Somatic variants in USP8, clustered in its 14-3-3 binding motif, release the protease from inhibitory 14-3-3
  binding. The cleaved, hyperactive enzyme deubiquitinates EGFR and so rescues it from lysosomal degradation,
  and the resulting sustained EGF signalling drives POMC transcription. In tumours with wild-type USP8, USP48
  and BRAF V600E variants converge on the same POMC promoter from a different direction, and the three are
  close to mutually exclusive - which is the observation that makes them look like alternative drivers of one
  pathway rather than incidental passengers.

  Two things follow clinically. The first is that the disease is defined by a failure of negative feedback:
  an autonomous corticotroph does not respond to the cortisol it is causing, which is why dexamethasone suppression
  is both the diagnostic test and a description of the lesion. The second is that the morbidity is not caused
  by the tumour, which is usually a small benign microadenoma, but by chronic glucocorticoid exposure downstream
  of it - the cardiovascular, metabolic, skeletal, immune and psychiatric burden that makes this a lethal disease
  if untreated and that only partly reverses on remission.'
disease_term:
  preferred_term: Cushing disease due to pituitary adenoma
  term:
    id: MONDO:0009050
    label: Cushing disease due to pituitary adenoma
synonyms:
- Cushing disease
- pituitary-dependent Cushing syndrome
- ACTH-secreting pituitary adenoma
- corticotroph adenoma
- pituitary ACTH hypersecretion
parents:
- Cushing's Syndrome
has_subtypes:
- name: USP8-mutant
  display_name: USP8-mutant corticotroph adenoma
  description: 'The commonest molecular subgroup. Individual series have reported anything from 35% to 62%,
    but a meta-analysis of 2,171 cases pools the prevalence at 31.1%, and much of the between-study spread
    turns out to track the sex ratio of the cohort rather than anything about the tumours. Variants cluster
    in the 14-3-3 binding motif encoded by exon 14, and are essentially confined to corticotroph adenomas -
    the same variants are not found in other pituitary adenoma types.

    The clinical profile is distinctive and internally tensioned: these patients are predominantly female,
    are diagnosed about four and a half years younger, and are *both* more likely to achieve postoperative
    remission and more likely to recur.'
  evidence:
  - reference: PMID:40392165
    reference_title: 'Prevalence and clinical associations of USP8 variants in corticotroph tumours: a systematic
      review and aggregate data meta-analysis of 2171 cases.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Pooled prevalence was 31.1% (95% CI, 26.5%-36.0%) and was higher in cases with functional tumours
      (34.1%; 95% CI, 29.4%-39.1%).
    explanation: The pooled prevalence estimate this entry uses in preference to individual-series figures.
  - reference: PMID:40392165
    reference_title: 'Prevalence and clinical associations of USP8 variants in corticotroph tumours: a systematic
      review and aggregate data meta-analysis of 2171 cases.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: patients with USP8 variant tumours are mostly female, diagnosed at younger age, more likely to
      achieve postoperative remission, but at a higher risk of recurrence than those with tumours carrying
      the reference allele
    explanation: The clinical associations, including the remission/recurrence pair that this entry treats
      as being in tension.
- name: USP48-mutant
  display_name: USP48-mutant corticotroph adenoma
  description: Recurrent p.M415I or p.M415V variants, found in about 23% of USP8 wild-type corticotroph adenomas.
    Converges on POMC promoter activation.
- name: BRAF V600E-mutant
  display_name: BRAF V600E-mutant corticotroph adenoma
  description: BRAF p.V600E in about 16% of USP8 wild-type corticotroph adenomas, acting through MAPK activation
    onto the same POMC promoter. Of the three drivers this is the one with a directly actionable inhibitor,
    and primary tumour cells carrying it respond to vemurafenib in vitro.
inheritance:
- name: Somatic
  description: The driver events are somatic and confined to the tumour. Cushing disease is overwhelmingly
    sporadic; germline predisposition exists (MEN1, and the familial isolated pituitary adenoma syndromes)
    but accounts for a small minority and is not modelled here.
pathophysiology:
- name: Somatic Driver Mutation in the Corticotroph
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  description: A somatic variant arises in a single anterior pituitary corticotroph and gives it a growth and
    secretory advantage. USP8 is the commonest driver, with variants clustering in the 14-3-3 protein binding
    motif rather than being distributed across the gene - a positional pattern that signals a gain-of-function
    mechanism rather than loss of the protease. In USP8 wild-type tumours the drivers are USP48 (p.M415I/p.M415V)
    and BRAF p.V600E. The three are close to mutually exclusive across a 169-tumour series, which is the evidence
    that they are alternative entries into one pathway. Loss-of-function variants in NR3C1, the glucocorticoid
    receptor, appear in a minority and attack the same autonomy from the feedback side.
  genetic_context:
    gene:
      preferred_term: USP8
      term:
        id: hgnc:12631
        label: USP8
    functional_impact_category: GAIN_OF_FUNCTION
    variant_origin: SOMATIC
  molecular_functions:
  - preferred_term: cysteine-type deubiquitinase activity
    modifier: GAIN_OF_FUNCTION
    term:
      id: GO:0004843
      label: cysteine-type deubiquitinase activity
  biological_processes:
  - preferred_term: protein deubiquitination
    modifier: INCREASED
    term:
      id: GO:0016579
      label: protein deubiquitination
  cell_types:
  - preferred_term: corticotroph
    term:
      id: CL:0002309
      label: corticotroph
  locations:
  - preferred_term: adenohypophysis
    term:
      id: UBERON:0002196
      label: adenohypophysis
  downstream:
  - target: Sustained EGFR Signalling
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:25485838
    reference_title: Mutations in the deubiquitinase gene USP8 cause Cushing's disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We found somatic mutations in the USP8 deubiquitinase gene in 4 of 10 adenomas. The mutations
      clustered in the 14-3-3 protein binding motif and enhanced the proteolytic cleavage and catalytic activity
      of USP8.
    explanation: Establishes the somatic USP8 driver and the positional clustering that indicates gain rather
      than loss of function.
  - reference: PMID:25675982
    reference_title: Recurrent gain-of-function USP8 mutations in Cushing's disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Targeted sequencing further identified a total of 17 types of USP8 variants in 67 of 108 ACTH-secreting
      PAs (62.04%). However, none of these mutations was detected in other types of PAs (n = 150).
    explanation: Gives the mutation frequency and the specificity to corticotroph adenomas, which is what makes
      USP8 a disease-defining driver rather than a general pituitary tumour event.
  - reference: PMID:30093687
    reference_title: Identification of recurrent USP48 and BRAF mutations in Cushing's disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: we report recurrent mutations in the deubiquitinase gene USP48 (predominantly encoding p.M415I
      or p.M415V; 21/91 subjects) and BRAF (encoding p.V600E; 15/91 subjects) in corticotroph adenomas with
      wild-type USP8
    explanation: Identifies the two drivers that account for a substantial share of USP8 wild-type tumours.
  - reference: PMID:30093687
    reference_title: Identification of recurrent USP48 and BRAF mutations in Cushing's disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: USP8 mutations are exclusive from mutations in either USP48 or BRAF in all the 169 cases
    explanation: The mutual exclusivity that supports treating the three as alternative drivers of a single
      pathway.
- name: Sustained EGFR Signalling
  biological_scale: CELLULAR
  mechanism_confidence: ESTABLISHED
  description: Wild-type USP8 is held inactive by 14-3-3 binding. Variants in that motif disrupt the interaction,
    allowing proteolytic cleavage into a hyperactive fragment which deubiquitinates EGFR. Ubiquitination is
    the signal that routes an activated receptor to the lysosome, so removing it rescues EGFR from degradation
    and returns it to the surface. The corticotroph therefore experiences continuous EGF pathway signalling
    from a normal amount of ligand - the defect is in receptor disposal, not in ligand supply. BRAF V600E reaches
    the same downstream state by constitutively activating the MAPK cascade below the receptor.
  biological_processes:
  - preferred_term: epidermal growth factor receptor signaling pathway
    modifier: GAIN_OF_FUNCTION
    term:
      id: GO:0007173
      label: epidermal growth factor receptor signaling pathway
  - preferred_term: ERK1 and ERK2 cascade
    modifier: INCREASED
    term:
      id: GO:0070371
      label: ERK1 and ERK2 cascade
  cell_types:
  - preferred_term: corticotroph
    term:
      id: CL:0002309
      label: corticotroph
  downstream:
  - target: POMC Transcription and ACTH Hypersecretion
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:25485838
    reference_title: Mutations in the deubiquitinase gene USP8 cause Cushing's disease.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Cleavage of USP8 led to increased deubiqutination of the EGF receptor, impairing its downregulation
      and sustaining EGF signaling.
    explanation: The mechanistic step from the mutant protease to sustained receptor signalling. (The spelling
      of "deubiqutination" is as published.)
  - reference: PMID:25675982
    reference_title: Recurrent gain-of-function USP8 mutations in Cushing's disease.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: These mutations aggregate within the 14-3-3 binding motif of USP8 and disrupt the interaction
      between USP8 and 14-3-3 protein, resulting in an elevated capacity to protect EGFR from lysosomal degradation.
    explanation: Names the specific regulatory interaction lost and the trafficking consequence.
  - reference: PMID:30093687
    reference_title: Identification of recurrent USP48 and BRAF mutations in Cushing's disease.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: BRAF V600E results in constitutive activation of the BRAF kinase activity and its downstream MAPK
      pathway
    explanation: Establishes the alternative route into the same signalling state in BRAF-mutant tumours.
- name: POMC Transcription and ACTH Hypersecretion
  biological_scale: CELLULAR
  mechanism_confidence: ESTABLISHED
  description: 'Proopiomelanocortin is the precursor from which ACTH is cleaved, so POMC promoter activity
    sets corticotroph output. All three drivers increase it. This convergence is the strongest argument that
    the molecular heterogeneity of these tumours is superficial: whatever the driver, the phenotype is excess
    ACTH, and the tumours are otherwise clinically indistinguishable.'
  biological_processes:
  - preferred_term: corticotropin secretion
    modifier: INCREASED
    term:
      id: GO:0051458
      label: corticotropin secretion
  cell_types:
  - preferred_term: corticotroph
    term:
      id: CL:0002309
      label: corticotroph
  downstream:
  - target: Loss of Glucocorticoid Negative Feedback
    causal_link_type: DIRECT
  - target: Adrenocortical Stimulation and Cortisol Excess
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:25485838
    reference_title: Mutations in the deubiquitinase gene USP8 cause Cushing's disease.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: USP8 mutants enhanced promoter activity of the gene encoding proopiomelanocortin.
    explanation: Direct demonstration that the USP8 driver acts on POMC transcription.
  - reference: PMID:30093687
    reference_title: Identification of recurrent USP48 and BRAF mutations in Cushing's disease.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Similar to USP8 mutants, both USP48 and BRAF mutants enhance the promoter activity and transcription
      of the gene encoding proopiomelanocortin (POMC), which is the precursor of ACTH, providing a potential
      mechanism for ACTH overproduction in corticotroph adenomas.
    explanation: The convergence of all three drivers on the same transcriptional output.
- name: Loss of Glucocorticoid Negative Feedback
  biological_scale: ORGANISM
  mechanism_confidence: ESTABLISHED
  description: A normal corticotroph suppresses ACTH when circulating cortisol rises. The adenoma does not,
    so the axis stabilises at a pathologically high setpoint with both ACTH and cortisol elevated - the combination
    that distinguishes this from adrenal Cushing syndrome, where ACTH is suppressed. The relative resistance
    is graded rather than absolute, which is what allows the high-dose dexamethasone test to separate pituitary
    from ectopic ACTH sources. In a minority of tumours the feedback lesion is direct, through loss-of-function
    variants in the glucocorticoid receptor gene itself.
  biological_processes:
  - preferred_term: corticotropin secretion
    modifier: GAIN_OF_FUNCTION
    term:
      id: GO:0051458
      label: corticotropin secretion
  downstream:
  - target: Adrenocortical Stimulation and Cortisol Excess
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:30093687
    reference_title: Identification of recurrent USP48 and BRAF mutations in Cushing's disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: loss-of-function mutations of the glucocorticoid receptor gene NR3C1
    explanation: Identifies the receptor whose loss removes feedback directly, in the minority of tumours carrying
      such variants.
  - reference: PMID:26156970
    reference_title: 'Cushing''s syndrome: update on signs, symptoms and biochemical screening.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The 1 mg overnight dexamethasone suppression test interrogates whether glucocorticoid negative
      feedback is normal.
    explanation: States that the standard screening test is a direct probe of the feedback lesion described
      by this node.
- name: Adrenocortical Stimulation and Cortisol Excess
  biological_scale: ORGANISM
  mechanism_confidence: ESTABLISHED
  description: Chronically elevated ACTH drives bilateral adrenocortical hyperplasia and sustained cortisol
    output. The adrenal is not diseased here - it is responding normally to an abnormal signal, which is why
    removing the pituitary source restores adrenal behaviour and why bilateral adrenalectomy works as a last-resort
    treatment despite doing nothing about the tumour.
  biological_processes:
  - preferred_term: glucocorticoid secretion
    modifier: INCREASED
    term:
      id: GO:0035933
      label: glucocorticoid secretion
  - preferred_term: cortisol biosynthetic process
    modifier: INCREASED
    term:
      id: GO:0034651
      label: cortisol biosynthetic process
  locations:
  - preferred_term: adrenal cortex
    term:
      id: UBERON:0001235
      label: adrenal cortex
  downstream:
  - target: Systemic Glucocorticoid Toxicity
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:30093687
    reference_title: Identification of recurrent USP48 and BRAF mutations in Cushing's disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Chronic elevation of ACTH stimulates the adrenal glands to secrete excessive glucocorticoids,
      which subsequently induces hypercortisolism
    explanation: States the ACTH-to-adrenal step explicitly.
- name: Systemic Glucocorticoid Toxicity
  biological_scale: ORGANISM
  mechanism_confidence: ESTABLISHED
  description: 'Every clinically important consequence of Cushing disease sits at this node rather than at
    the tumour. Chronic cortisol excess produces central adiposity with peripheral wasting, proximal myopathy,
    dermal atrophy with wide purple striae, insulin resistance and diabetes, hypertension, osteoporosis, hypercoagulability,
    immunosuppression and mood and cognitive disturbance. The burden is cumulative and outlives the biochemistry:
    mortality is raised relative to the general population, and quality of life after remission does not fully
    normalise.'
  evidence:
  - reference: PMID:26156970
    reference_title: 'Cushing''s syndrome: update on signs, symptoms and biochemical screening.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In addition to classical features of glucocorticoid excess, such as proximal muscle weakness and
      wide purple striae, patients may present with the associated comorbidities that are caused by hypercortisolism.
      These include cardiovascular disease, thromboembolic disease, psychiatric and cognitive deficits, and
      infections.
    explanation: Enumerates the multisystem toxicity attributed directly to the cortisol excess.
  - reference: PMID:26156970
    reference_title: 'Cushing''s syndrome: update on signs, symptoms and biochemical screening.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Endogenous pathologic hypercortisolism, or Cushing's syndrome, is associated with poor quality
      of life, morbidity, and increased mortality.
    explanation: Establishes that the outcome burden is attributable to the hypercortisolism itself.
phenotypes:
- category: Endocrine
  name: Elevated Circulating Cortisol
  frequency: VERY_FREQUENT
  description: The defining biochemical abnormality, with loss of the normal circadian nadir so that late-night
    cortisol is inappropriately high.
  phenotype_term:
    preferred_term: Increased circulating cortisol level
    term:
      id: HP:0003118
      label: Increased circulating cortisol level
  evidence:
  - reference: PMID:26156970
    reference_title: 'Cushing''s syndrome: update on signs, symptoms and biochemical screening.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Patients with Cushing's syndrome lose this diurnal nadir and have increased serum and salivary
      cortisol values at bedtime compared with obese and pseudo-Cushing's patients
    explanation: Documents both the elevation and the loss of circadian rhythm that defines it.
- category: Endocrine
  name: Elevated Circulating ACTH
  frequency: VERY_FREQUENT
  description: ACTH is inappropriately normal or high in the face of hypercortisolism. This is what makes the
    disease ACTH-dependent and separates it at the first diagnostic fork from adrenal causes of Cushing syndrome.
  phenotype_term:
    preferred_term: Increased circulating ACTH level
    term:
      id: HP:0003154
      label: Increased circulating ACTH level
  evidence:
  - reference: PMID:25675982
    reference_title: Recurrent gain-of-function USP8 mutations in Cushing's disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cushing's disease, also known as adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas
      (PAs) that cause excess cortisol production
    explanation: States the ACTH-secreting character of the tumour that produces this phenotype.
- category: Metabolic
  name: Central Obesity
  frequency: VERY_FREQUENT
  description: Truncal fat accumulation with relative sparing or wasting of the limbs - the redistribution
    rather than the total that is characteristic.
  phenotype_term:
    preferred_term: Truncal obesity
    term:
      id: HP:0001956
      label: Truncal obesity
  evidence:
  - reference: PMID:26156970
    reference_title: 'Cushing''s syndrome: update on signs, symptoms and biochemical screening.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: wasting of the extremities with increased fat in the abdomen, torso and face
    explanation: Describes the truncal redistribution of fat with peripheral wasting.
  - reference: PMID:42572239
    reference_title: 'Clinical Profile, Biochemical Characteristics, and Surgical Outcomes in Cushing Disease:
      An Age-Stratified Analysis of a Large Tertiary-Care Cohort.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Classical cushingoid features were highly prevalent, including weight gain (79.4%), centripetal
      obesity (62.5%), hyperpigmentation (61.0%), and proximal myopathy (60.6%).
    explanation: Counted frequency for centripetal obesity in a 277-patient cohort.
- category: Dermatologic
  name: Wide Purple Striae
  frequency: FREQUENT
  description: Broad violaceous striae from dermal atrophy and collagen catabolism. Width and colour are what
    distinguish these from the common striae of weight change, and they are among the more discriminating physical
    signs.
  phenotype_term:
    preferred_term: Striae distensae
    term:
      id: HP:0001065
      label: Striae distensae
  evidence:
  - reference: PMID:26156970
    reference_title: 'Cushing''s syndrome: update on signs, symptoms and biochemical screening.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: proximal muscle weakness, wasting of the extremities with increased fat in the abdomen, torso
      and face, and wide purple striae, suggest marked hypercortisolism
    explanation: Names wide purple striae among the discriminating features of marked hypercortisolism.
- category: Musculoskeletal
  name: Proximal Myopathy
  frequency: FREQUENT
  description: Weakness of proximal limb girdle muscles from glucocorticoid-induced catabolism, typically noticed
    as difficulty rising from a chair or climbing stairs.
  phenotype_term:
    preferred_term: Proximal muscle weakness
    term:
      id: HP:0003701
      label: Proximal muscle weakness
  evidence:
  - reference: PMID:26156970
    reference_title: 'Cushing''s syndrome: update on signs, symptoms and biochemical screening.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: classical features of glucocorticoid excess, such as proximal muscle weakness and wide purple
      striae
    explanation: Identifies proximal muscle weakness as a classical feature of glucocorticoid excess.
  - reference: PMID:42572239
    reference_title: 'Clinical Profile, Biochemical Characteristics, and Surgical Outcomes in Cushing Disease:
      An Age-Stratified Analysis of a Large Tertiary-Care Cohort.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Classical cushingoid features were highly prevalent, including weight gain (79.4%), centripetal
      obesity (62.5%), hyperpigmentation (61.0%), and proximal myopathy (60.6%).
    explanation: Counted frequency for proximal myopathy (60.6%).
- category: Cardiovascular
  name: Hypertension
  frequency: FREQUENT
  description: Raised blood pressure from mineralocorticoid receptor activation by excess cortisol together
    with vascular and renal glucocorticoid effects. It is one of the comorbidities that makes the disease lethal
    if untreated, and also one of the least specific, being common in the population Cushing disease is screened
    out of.
  phenotype_term:
    preferred_term: Hypertension
    term:
      id: HP:0000822
      label: Hypertension
  evidence:
  - reference: PMID:26156970
    reference_title: 'Cushing''s syndrome: update on signs, symptoms and biochemical screening.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: most of the signs and symptoms of Cushing's syndrome are common in the general population (e.g.,
      hypertension and weight gain) and not all are present in every patient
    explanation: PARTIAL because the source names hypertension as a feature while making the point that it
      is non-specific, which is the correct strength for this claim rather than a frequency estimate.
  - reference: PMID:42572239
    reference_title: 'Clinical Profile, Biochemical Characteristics, and Surgical Outcomes in Cushing Disease:
      An Age-Stratified Analysis of a Large Tertiary-Care Cohort.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the recorded burden of cardiometabolic comorbidities at tertiary-care assessment, including hypertension
      (70.8%) and diabetes mellitus (48.0%), was higher in older age groups
    explanation: Supplies a counted frequency (70.8%) in a 277-patient Cushing disease cohort, which the earlier
      non-specificity snippet did not.
- category: Metabolic
  name: Diabetes Mellitus
  frequency: FREQUENT
  description: Glucocorticoid-driven insulin resistance and hepatic gluconeogenesis producing impaired glucose
    tolerance or overt diabetes.
  phenotype_term:
    preferred_term: Diabetes mellitus
    term:
      id: HP:0000819
      label: Diabetes mellitus
  evidence:
  - reference: PMID:26156970
    reference_title: 'Cushing''s syndrome: update on signs, symptoms and biochemical screening.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the frequency of many features of Cushing's syndrome were similar in both groups, including diabetes,
      hypertension, acne, hirsutism and menstrual disorders
    explanation: PARTIAL because the source establishes diabetes as a recognised feature while explicitly reporting
      that it did not discriminate Cushing syndrome from pseudo-Cushing states.
  - reference: PMID:42572239
    reference_title: 'Clinical Profile, Biochemical Characteristics, and Surgical Outcomes in Cushing Disease:
      An Age-Stratified Analysis of a Large Tertiary-Care Cohort.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the recorded burden of cardiometabolic comorbidities at tertiary-care assessment, including hypertension
      (70.8%) and diabetes mellitus (48.0%), was higher in older age groups
    explanation: Supplies the counted diabetes frequency (48.0%) in a Cushing disease cohort rather than the
      pseudo-Cushing comparison used previously.
- category: Musculoskeletal
  name: Osteoporosis
  frequency: FREQUENT
  description: Reduced bone mineral density from suppressed osteoblast function and increased resorption, with
    fragility fractures - notably vertebral - a presenting feature in some patients.
  phenotype_term:
    preferred_term: Osteoporosis
    term:
      id: HP:0000939
      label: Osteoporosis
  evidence:
  - reference: PMID:26156970
    reference_title: 'Cushing''s syndrome: update on signs, symptoms and biochemical screening.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Easy bruising and osteoporosis were more common in patients with Cushing's syndrome
    explanation: Reports osteoporosis as discriminating Cushing syndrome from pseudo-Cushing states in a comparative
      study.
- category: Neuropsychiatric
  name: Mood and Cognitive Disturbance
  frequency: FREQUENT
  description: Emotional lability, irritability, depression, insomnia and impaired short-term memory. Long
    recognised as an early clue, and among the features that recover least completely after biochemical remission.
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: PMID:26156970
    reference_title: 'Cushing''s syndrome: update on signs, symptoms and biochemical screening.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Mood and cognitive changes have long been recognized as important clues to the presence of Cushing's
      syndrome
    explanation: Establishes the neuropsychiatric component as a recognised part of the syndrome.
- category: Hematologic
  name: Easy Bruising
  frequency: FREQUENT
  description: Bruising from dermal and perivascular connective tissue atrophy under chronic glucocorticoid
    exposure.
  phenotype_term:
    preferred_term: Bruising susceptibility
    term:
      id: HP:0000978
      label: Bruising susceptibility
  evidence:
  - reference: PMID:26156970
    reference_title: 'Cushing''s syndrome: update on signs, symptoms and biochemical screening.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Easy bruising and osteoporosis were more common in patients with Cushing's syndrome
    explanation: Reports easy bruising as discriminating for Cushing syndrome in a comparative study.
- category: Hematologic
  name: Hypercoagulability and Venous Thromboembolism
  frequency: OCCASIONAL
  description: 'Cortisol excess raises coagulation factor production and impairs fibrinolysis, producing a
    prothrombotic state. It matters most around surgery: pooled postoperative venous thromboembolism after
    transsphenoidal surgery for Cushing disease is 2%, with 0.2% VTE-associated mortality. The important point
    is that removing the adenoma does not immediately reverse the hypercoagulability, so the risk window outlasts
    the operation.'
  phenotype_term:
    preferred_term: Venous thrombosis
    term:
      id: HP:0004936
      label: Venous thrombosis
  evidence:
  - reference: PMID:39182834
    reference_title: 'Venous Thromboembolism and Prevention Strategies in Patients with Cushing''s Disease:
      A Systematic Review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Pooled postoperative VTE incidence in patients undergoing transsphenoidal surgery for CD was 2%
      (58 out of 2997).
    explanation: The pooled postoperative VTE rate quoted here.
  - reference: PMID:39182834
    reference_title: 'Venous Thromboembolism and Prevention Strategies in Patients with Cushing''s Disease:
      A Systematic Review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: highlighting that surgical resection of the corticotroph adenoma does not necessarily result in
      immediate resolution of hypercoagulability
    explanation: Supports the statement that the thrombotic risk window outlasts the operation.
- category: Dermatologic
  name: Hyperpigmentation
  frequency: FREQUENT
  description: Skin darkening from the melanocortin activity of ACTH and of the other POMC-derived peptides
    secreted alongside it. It is the third-commonest sign in a large cohort at 61%, and it is mechanistically
    specific to the ACTH-dependent forms - it does not occur in adrenal Cushing syndrome, where ACTH is suppressed.
  phenotype_term:
    preferred_term: Hyperpigmentation of the skin
    term:
      id: HP:0000953
      label: Hyperpigmentation of the skin
  evidence:
  - reference: PMID:42572239
    reference_title: 'Clinical Profile, Biochemical Characteristics, and Surgical Outcomes in Cushing Disease:
      An Age-Stratified Analysis of a Large Tertiary-Care Cohort.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Classical cushingoid features were highly prevalent, including weight gain (79.4%), centripetal
      obesity (62.5%), hyperpigmentation (61.0%), and proximal myopathy (60.6%).
    explanation: The counted frequency of hyperpigmentation in a 277-patient Cushing disease cohort.
- category: Reproductive
  name: Menstrual Irregularity
  frequency: FREQUENT
  description: Oligomenorrhoea or amenorrhoea from cortisol suppression of the hypothalamic-pituitary-gonadal
    axis, and one of the manifestations reported more often in younger patients. Relevant because it is a common
    route of referral - to gynaecology rather than endocrinology - and so a common reason the diagnosis is
    late.
  phenotype_term:
    preferred_term: Irregular menstruation
    term:
      id: HP:0000858
      label: Irregular menstruation
  evidence:
  - reference: PMID:42572239
    reference_title: 'Clinical Profile, Biochemical Characteristics, and Surgical Outcomes in Cushing Disease:
      An Age-Stratified Analysis of a Large Tertiary-Care Cohort.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Younger patients showed a relatively higher recorded frequency of dermatological and reproductive
      manifestations, including striae, acne, and menstrual irregularities
    explanation: Reports menstrual irregularity among the reproductive manifestations, and its age distribution.
- category: Immunologic
  name: Susceptibility to Infection
  frequency: OCCASIONAL
  description: Glucocorticoid-induced immunosuppression. Modelled explicitly because infection is one of the
    two leading contributors to the excess mortality this entry records, alongside cardiovascular disease -
    so it is a cause of death and not only a complication.
  phenotype_term:
    preferred_term: Recurrent infections
    term:
      id: HP:0002719
      label: Recurrent infections
  evidence:
  - reference: PMID:26156970
    reference_title: 'Cushing''s syndrome: update on signs, symptoms and biochemical screening.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: These include cardiovascular disease, thromboembolic disease, psychiatric and cognitive deficits,
      and infections.
    explanation: Lists infection among the comorbidities caused by hypercortisolism.
  - reference: PMID:30715394
    reference_title: 'Overall and Disease-Specific Mortality in Patients With Cushing Disease: A Swedish Nationwide
      Study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Excess mortality was also found associated with infections and suicide.
    explanation: Establishes infection as a contributor to the excess mortality, which is why this is modelled
      rather than left in prose.
clinical_burden:
  burden_level: HIGH
  rationale: 'Cushing disease roughly doubles mortality. In an unselected Swedish nationwide cohort of 502
    patients the standardised mortality ratio was 2.5, with cardiovascular death the commonest cause and excess
    mortality also from infection and suicide. Crucially the excess does not disappear on cure: for patients
    in remission the SMR was still 1.9. That residual is the strongest argument in this entry for treating
    the accumulated glucocorticoid damage, rather than the tumour, as the thing that determines outcome.'
  evidence:
  - reference: PMID:30715394
    reference_title: 'Overall and Disease-Specific Mortality in Patients With Cushing Disease: A Swedish Nationwide
      Study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The observed number of deaths was 133 vs 54 expected, resulting in an overall SMR of 2.5 (95%
      CI, 2.1 to 2.9). The commonest cause of death was cardiovascular diseases (SMR, 3.3; 95% CI, 2.6 to 4.3).
    explanation: The nationwide mortality estimate and its leading cause.
  - reference: PMID:30715394
    reference_title: 'Overall and Disease-Specific Mortality in Patients With Cushing Disease: A Swedish Nationwide
      Study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: For patients in remission, the SMR was 1.9 (95% CI, 1.5 to 2.3)
    explanation: The residual excess mortality after remission, which this entry treats as the key burden finding.
genetic:
- name: USP8
  gene_term:
    preferred_term: USP8
    term:
      id: hgnc:12631
      label: USP8
  relationship_type: CAUSATIVE
  notes: Somatic, not germline. The variants cluster in the 14-3-3 binding motif and are gain-of-function,
    which is worth stating because the intuitive reading of a mutated deubiquitinase in a tumour is loss of
    function.
  evidence:
  - reference: PMID:25485838
    reference_title: Mutations in the deubiquitinase gene USP8 cause Cushing's disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: our data show that dominant mutations in USP8 cause Cushing's disease via activation of EGF receptor
      signaling
    explanation: The causal conclusion of the discovery study.
- name: USP48
  gene_term:
    preferred_term: USP48
    term:
      id: hgnc:18533
      label: USP48
  relationship_type: CAUSATIVE
  notes: Somatic driver in USP8 wild-type tumours; recurrent p.M415I and p.M415V.
  evidence:
  - reference: PMID:30093687
    reference_title: Identification of recurrent USP48 and BRAF mutations in Cushing's disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Combining the data from whole-exome and targeted sequencing, which included a total of 91 samples,
      we found that 16.5% of the cases (15/91) had BRAF V600E mutations and 23.1% of the cases (21/91) harbored
      USP48 mutations.
    explanation: Gives the USP48 mutation frequency among USP8 wild-type corticotroph adenomas - 23.1% of 91
      cases - alongside the BRAF figure from the same combined analysis.
- name: BRAF
  gene_term:
    preferred_term: BRAF
    term:
      id: hgnc:1097
      label: BRAF
  relationship_type: CAUSATIVE
  notes: Somatic p.V600E in USP8 wild-type tumours. The only one of the three drivers with an established inhibitor,
    which makes molecular subtyping potentially actionable rather than purely descriptive.
  evidence:
  - reference: PMID:30093687
    reference_title: Identification of recurrent USP48 and BRAF mutations in Cushing's disease.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: primary corticotroph tumor cells harboring BRAF V600E are sensitive to the BRAF inhibitor vemurafenib
    explanation: The result that makes BRAF status therapeutically relevant.
- name: NR3C1
  gene_term:
    preferred_term: NR3C1
    term:
      id: hgnc:7978
      label: NR3C1
  relationship_type: MODIFIER
  notes: Loss-of-function variants in the glucocorticoid receptor, found in a minority of tumours. Modelled
    as a modifier rather than a primary driver because the reported cases are few and it removes feedback rather
    than conferring the proliferative advantage the other three do.
  evidence:
  - reference: PMID:30093687
    reference_title: Identification of recurrent USP48 and BRAF mutations in Cushing's disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: loss-of-function mutations of the glucocorticoid receptor gene NR3C1
    explanation: PARTIAL because the source identifies NR3C1 among candidate lesions in a small number of tumours
      rather than establishing it as a recurrent driver on the scale of the other three. The source describes
      NR3C1 as a critical negative regulator of ACTH production, but that phrase is interrupted by inline citation
      markers in the cached text and so is not quoted here.
prevalence:
- population: Sweden
  measure_type: ANNUAL_INCIDENCE
  prevalence_class: BAND_1_9_PER_1000000
  rate_per_100000: 0.16
  rate_low: 0.14
  rate_high: 0.18
  notes: 1.6 cases per million per year (95% CI 1.4-1.8), normalised to 0.16 per 100,000. From a nationwide
    registry cohort in which every diagnosis was validated against clinical, biochemical, imaging and histopathological
    data - which matters here, because only 41% of the 1,317 patients carrying a Cushing diagnostic code turned
    out to have confirmed Cushing disease. An unvalidated code-based count would overstate this figure roughly
    2.5-fold.
  evidence:
  - reference: PMID:30799512
    reference_title: 'The incidence of Cushing''s disease: a nationwide Swedish study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The mean (95% confidence interval) annual incidence between 1987 and 2013 of confirmed CD was
      1.6 (1.4-1.8) cases per million.
    explanation: The validated nationwide incidence estimate this record normalises.
  - reference: PMID:30799512
    reference_title: 'The incidence of Cushing''s disease: a nationwide Swedish study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Of 1317 patients identified, 534 (41%) had confirmed CD.
    explanation: The validation yield, which is why this entry prefers this figure over a code-based or secondarily
      cited one.
diagnosis:
- name: Screening for Hypercortisolism
  description: 'Two of three tests are used to establish endogenous hypercortisolism before the cause is pursued:
    24-hour urine free cortisol, late-night salivary cortisol, and the 1 mg overnight dexamethasone suppression
    test. Exogenous glucocorticoid use has to be excluded first, and each test has a documented false-positive
    profile - oral oestrogens raise cortisol-binding globulin, CYP3A4-interacting drugs alter dexamethasone
    clearance, and the pseudo-Cushing states raise urine free cortisol physiologically.'
  diagnosis_term:
    preferred_term: laboratory procedure
    term:
      id: NCIT:C25294
      label: Laboratory Procedure
  evidence:
  - reference: PMID:26156970
    reference_title: 'Cushing''s syndrome: update on signs, symptoms and biochemical screening.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'The guideline recommends using two of three screening tests to establish the diagnosis: UFC,
      late night salivary cortisol or 1mg dexamethasone suppression test'
    explanation: States the recommended screening strategy this entry describes.
- name: Pituitary MRI and Inferior Petrosal Sinus Sampling
  description: Once ACTH-dependent hypercortisolism is established, the question is whether the source is pituitary
    or ectopic. MRI finds the adenoma in most but not all cases - a substantial minority are MRI-negative,
    and those patients have measurably lower surgical remission rates, which is why petrosal sinus sampling
    retains a role.
  diagnosis_term:
    preferred_term: magnetic resonance imaging procedure
    term:
      id: NCIT:C16809
      label: Magnetic Resonance Imaging
  evidence:
  - reference: PMID:34415482
    reference_title: 'Surgical outcome of transsphenoidal surgery in Cushing''s disease: a case series of 1106
      patients from a single center over 30 years.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The initial remission rate in patients with pseudocapsule-based extracapsular resection (88.1%),
      MRI-visible adenoma (74.2%) was higher than that in patients without pseudocapsule-based extracapsular
      resection (77.1%), and with MRI-negative results (64.5%)
    explanation: Quantifies the outcome difference between MRI-visible and MRI-negative disease that motivates
      further localisation.
treatments:
- name: Transsphenoidal Selective Adenomectomy
  therapeutic_modality: SURGERY
  description: 'First-line treatment and the only one that addresses the lesion itself. Reported initial remission
    in a 1106-patient single-centre series was 72.5%, with about a quarter left in persistent hypercortisolism.
    Remission is substantially lower with invasive tumours, macroadenomas, pathologically negative specimens
    and repeat surgery, so the figure quoted for any given patient depends on which of those apply. Remission
    is not the end of the story: recurrence occurred in 27.4% of patients over a median 38 months in one operated
    series, and is markedly higher after macroadenoma resection than after microadenoma or no visible lesion
    (45% versus 19%). An early postoperative nadir cortisol at or below 3 mcg/dL is the best available predictor
    of durable remission.'
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  target_mechanisms:
  - target: POMC Transcription and ACTH Hypersecretion
    treatment_effect: INHIBITS
    description: Removes the autonomous ACTH source, which is why it is the only treatment that can restore
      a normal axis rather than manage its output.
  evidence:
  - reference: PMID:34415482
    reference_title: 'Surgical outcome of transsphenoidal surgery in Cushing''s disease: a case series of 1106
      patients from a single center over 30 years.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: After surgery, the overall postoperative initial remission rate was 72.5, and 27.5% of patients
      maintained persistent hypercortisolism.
    explanation: The remission rate this entry reports, from the largest single-centre series available.
  - reference: PMID:34415482
    reference_title: 'Surgical outcome of transsphenoidal surgery in Cushing''s disease: a case series of 1106
      patients from a single center over 30 years.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: preoperative invasiveness based on MRI, intraoperative invasiveness, macroadenomas pathologically
      negative, and repeat TSS are related to lower initial remission rates
    explanation: The determinants that qualify the headline remission figure.
  - reference: PMID:40257708
    reference_title: 'The prevalence and predictors of Cushing disease recurrence: a 10-year experience of
      a pituitary tumor center of excellence.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Surgical remission was achieved in 81% of patients, but recurrence occurred in 27.4% of cases
      after a median follow up period of 38 months (range 16-101).
    explanation: The recurrence rate, which this entry now reports alongside remission because Cushing disease
      is a relapsing condition.
  - reference: PMID:40257708
    reference_title: 'The prevalence and predictors of Cushing disease recurrence: a 10-year experience of
      a pituitary tumor center of excellence.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Recurrence rates were lower in patients with microadenomas/no visible lesion compared to those
      with macroadenomas (19% vs 45%; p = 0.03).
    explanation: The tumour-size stratification of recurrence risk.
- name: Osilodrostat
  therapeutic_modality: SMALL_MOLECULE
  description: An oral 11-beta-hydroxylase inhibitor that blocks the final step of cortisol synthesis in the
    adrenal. It treats the consequence rather than the cause - the tumour is untouched and ACTH typically rises
    - which is also why hypocortisolism and accumulation of adrenal steroid precursors are the characteristic
    adverse effects rather than incidental ones. A second Phase III trial, LINC 4, tested it against placebo
    from the outset rather than in a withdrawal design and found 77% versus 8% achieving normal urinary free
    cortisol at 12 weeks - so the effect is not an artefact of the LINC 3 withdrawal structure.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: osilodrostat
      term:
        id: CHEBI:755118
        label: osilodrostat
  target_mechanisms:
  - target: Adrenocortical Stimulation and Cortisol Excess
    treatment_effect: INHIBITS
    description: Inhibits adrenal steroidogenesis downstream of ACTH, lowering cortisol without altering the
      pituitary lesion.
  evidence:
  - reference: PMID:32730798
    reference_title: 'Efficacy and safety of osilodrostat in patients with Cushing''s disease (LINC 3): a multicentre
      phase III study with a double-blind, randomised withdrawal phase.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: More patients maintained a complete response with osilodrostat versus with placebo at week 34
      (31 [86%] vs ten [29%]; odds ratio 13·7 [95% CI 3·7-53·4]; p<0·0001).
    explanation: The randomised withdrawal result establishing efficacy against placebo.
  - reference: PMID:32730798
    reference_title: 'Efficacy and safety of osilodrostat in patients with Cushing''s disease (LINC 3): a multicentre
      phase III study with a double-blind, randomised withdrawal phase.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hypocortisolism occurred in 70 (51%) patients and adverse events related to adrenal hormone precursors
      occurred in 58 (42%) patients.
    explanation: The adverse-effect profile that follows mechanistically from blocking the final synthetic
      step.
  - reference: PMID:35325149
    reference_title: Randomized Trial of Osilodrostat for the Treatment of Cushing Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: At week 12, significantly more osilodrostat (77%) than placebo (8%) patients achieved mUFC ≤ ULN
      (odds ratio 43.4; 95% CI 7.1, 343.2; P < 0.0001).
    explanation: The LINC 4 placebo-controlled result, which corroborates LINC 3 with a different trial design.
- name: Pasireotide
  therapeutic_modality: PEPTIDE
  description: 'A multi-receptor somatostatin analogue with affinity for SSTR5, which corticotroph adenomas
    express. Unlike osilodrostat it acts on the tumour rather than the adrenal. In the long-acting Phase III
    extension, urinary free cortisol was at or below the upper limit of normal in about half of patients at
    last assessment and clinical improvements were sustained. The cost is metabolic and predictable rather
    than idiosyncratic: SSTR5 agonism impairs insulin secretion, and hyperglycaemia-related adverse events
    occurred in 39.5% of patients.'
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: pasireotide
      term:
        id: CHEBI:72312
        label: pasireotide
  target_mechanisms:
  - target: POMC Transcription and ACTH Hypersecretion
    treatment_effect: INHIBITS
    description: Suppresses ACTH secretion from the adenoma through somatostatin receptor agonism.
  evidence:
  - reference: PMID:31465533
    reference_title: 'Long-term efficacy and safety of once-monthly pasireotide in Cushing''s disease: A Phase
      III extension study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: mUFC was ≤ULN in 42/81 (51.9%), 13/81 (16.0%) and 43/81 (53.1%) patients at extension baseline,
      month (M) 36 and last assessment.
    explanation: The biochemical response rates from the long-acting pasireotide Phase III extension.
  - reference: PMID:31465533
    reference_title: 'Long-term efficacy and safety of once-monthly pasireotide in Cushing''s disease: A Phase
      III extension study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Long-acting pasireotide provided sustained biochemical and clinical improvements, with no new
      safety signals emerging, supporting its use as an effective long-term therapy for CD.
    explanation: The study's conclusion on sustained efficacy.
  - reference: PMID:31465533
    reference_title: 'Long-term efficacy and safety of once-monthly pasireotide in Cushing''s disease: A Phase
      III extension study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hyperglycaemia-related AEs occurred in 39.5% of patients.
    explanation: The class effect that follows from SSTR5 agonism impairing insulin secretion.
- name: Bilateral Adrenalectomy
  therapeutic_modality: SURGERY
  description: Definitive control of hypercortisolism for refractory disease, at the cost of permanent adrenal
    insufficiency and the risk of Nelson syndrome as the unresected corticotroph tumour loses what feedback
    restraint it had. It cures the cortisol excess while leaving the actual lesion in place, which is an unusually
    clear illustration of where in this pathograph the morbidity sits.
  treatment_term:
    preferred_term: adrenalectomy
    term:
      id: NCIT:C15177
      label: Adrenalectomy
  target_mechanisms:
  - target: Adrenocortical Stimulation and Cortisol Excess
    treatment_effect: INHIBITS
    description: Removes the effector organ, abolishing cortisol output regardless of ACTH.
  evidence:
  - reference: PMID:34687601
    reference_title: 'Consensus on diagnosis and management of Cushing''s disease: a guideline update.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cushing's disease requires accurate diagnosis, careful treatment selection, and long-term management
      to optimise patient outcomes.
    explanation: PARTIAL because the abstract establishes that treatment selection is the subject of consensus
      recommendation without stating an adrenalectomy-specific outcome. The specific claims in this entry's
      description are not carried by this snippet.
experimental_models:
- name: AtT-20 murine corticotroph tumour cell line
  experimental_model_type: CELL_LINE
  organism:
    preferred_term: house mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  publication: PMID:28505327
  description: The standard in vitro model for ACTH-secreting tumours, used in culture and as nude-mouse xenografts.
    Its value is that it couples a measurable ACTH output to POMC transcription, so a candidate that acts on
    the transcriptional node can be read out directly.
  modeled_mechanisms:
  - target: POMC Transcription and ACTH Hypersecretion
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: Reproduces regulated POMC transcription and ACTH secretion in a corticotroph tumour cell,
      which is the node this entry treats as the convergence point of all three drivers.
    limitations: AtT-20 cells do not carry the human USP8 hotspot variant, and no widely used genetically engineered
      mouse reproduces USP8-driven Cushing disease. So the line models the output of the pathway without modelling
      the lesion that drives it - it is informative about POMC/ACTH regulation and uninformative about the
      driver biology that distinguishes this disease from any other cause of corticotroph ACTH excess.
    readouts:
    - name: Secreted ACTH
      target: POMC Transcription and ACTH Hypersecretion
      direction: DECREASED
      interpretation: HDAC inhibition lowers secreted ACTH and POMC transcription together, supporting POMC
        transcription as the controlling step for ACTH output in this model.
      evidence:
      - reference: PMID:28505327
        reference_title: Histone Deacetylase Inhibitor SAHA Is a Promising Treatment of Cushing Disease.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: early (3-hour) significant decline (70%; P < 0.0001) of secreted ACTH and diminished POMC
          transcription was observed with SAHA
        explanation: The paired ACTH and POMC measurement behind this readout.
    evidence:
    - reference: PMID:28505327
      reference_title: Histone Deacetylase Inhibitor SAHA Is a Promising Treatment of Cushing Disease.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Testing the efficacy of suberoylanilide hydroxamic acid (SAHA) on human and murine ACTH-secreting
        tumor (AtT-20) cells.
      explanation: Establishes AtT-20 as the model system used for ACTH-secreting tumour pharmacology, alongside
        human-derived corticotroph tumour cells.
discussions:
- discussion_id: cd_usp8_status_not_yet_actionable
  kind: KNOWLEDGE_GAP
  attaches_to:
  - has_subtypes#USP8-mutant
  - treatments#Transsphenoidal Selective Adenomectomy
  prompt: Does knowing a corticotroph adenoma's driver genotype change what should be done for the patient?
  rationale: 'The molecular subtyping of corticotroph adenomas is now well established - three recurrent drivers,
    close to mutually exclusive, each converging on POMC - and it has so far changed management for almost
    nobody. Surgery is offered on the same terms regardless of genotype, and genotype is not routinely determined
    because the tissue is only available after the operation that would have been done anyway.

    It is not that the prognostic signal is absent. A meta-analysis of 2,171 cases found USP8-variant tumours
    significantly more likely to achieve postoperative remission (OR 1.76) and, at the same time, significantly
    more likely to recur (OR 2.38). Those two point in opposite directions over different time horizons, so
    USP8 status does not resolve into a single prognostic statement a surgeon can act on at the point of decision
    - it says this patient is more likely to be in remission next month and more likely to relapse later. Whether
    that should change follow-up intensity rather than initial management has not been tested, and the pooled
    data are retrospective and heterogeneous enough that the authors attribute much of the between-study variation
    to cohort sex ratio.

    And the pooled signal is contested by the primary literature. The largest single USP8 series reports that
    recurrence rate and recurrence period were unrelated to USP8 status, and a separate operated cohort analysing
    recurrence predictors directly found USP8 and USP48 status not associated with recurrence. So the meta-analytic
    OR of 2.38 is not corroborated by either primary series that looked for it, which is a stronger reason
    than heterogeneity alone to treat USP8 status as prognostically unsettled.


    BRAF V600E is the cleaner opportunity and the more specific one. It is directly druggable, primary tumour
    cells carrying it respond to vemurafenib in vitro, and it accounts for roughly one in six USP8 wild-type
    tumours. No trial has tested it.

    The gap is therefore not knowledge of the biology, which is unusually well worked out for a rare endocrine
    tumour, and no longer quite "no association has been shown" either. It is that no study has linked driver
    genotype prospectively to a decision a clinician makes.'
  proposed_experiments:
  - experiment_id: cd_driver_genotype_vs_surgical_outcome
    name: Prospective association of driver genotype with post-surgical remission and recurrence
    description: Genotype resected corticotroph adenomas for USP8, USP48 and BRAF in a prospective surgical
      cohort and relate driver status to initial remission and to recurrence over long-term follow-up, adjusting
      for the tumour characteristics already known to predict outcome - invasiveness, size and MRI visibility.
    would_support:
    - has_subtypes#USP8-mutant
    supporting_outcome:
    - Driver genotype predicts remission or recurrence prospectively after adjustment for tumour size, invasiveness
      and cohort sex ratio, reproducing the direction of the pooled retrospective estimates.
    refuting_outcome:
    - Genotype adds nothing once size, invasiveness and sex are accounted for, meaning the pooled association
      is confounded by the cohort composition the meta-regression already implicated.
  evidence:
  - reference: PMID:40392165
    reference_title: 'Prevalence and clinical associations of USP8 variants in corticotroph tumours: a systematic
      review and aggregate data meta-analysis of 2171 cases.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: USP8 status was associated with higher odds for postoperative remission (OR 1.76, 95% CI, 1.18-2.63)
      and recurrence (OR 2.38, 95% CI, 1.03-5.48).
    explanation: The pooled association this discussion is built around.
  - reference: PMID:25675982
    reference_title: Recurrent gain-of-function USP8 mutations in Cushing's disease.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: the recurrence rate and the average recurrence period were unrelated to the USP8 mutational status
    explanation: A primary series disagreeing with the pooled recurrence estimate.
  - reference: PMID:40257708
    reference_title: 'The prevalence and predictors of Cushing disease recurrence: a 10-year experience of
      a pituitary tumor center of excellence.'
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: Age, gender, tumor diameter, USP8 and USP48 mutational status, cortisol on the 7th post-operative
      day and, ACTH immuno-positivity in histology were not associated with recurrence.
    explanation: A second, independent operated cohort that looked directly for a genotype-recurrence association
      and did not find one.
references:
- reference: PMID:25485838
  title: Mutations in the deubiquitinase gene USP8 cause Cushing's disease.
- reference: PMID:25675982
  title: Recurrent gain-of-function USP8 mutations in Cushing's disease.
- reference: PMID:30093687
  title: Identification of recurrent USP48 and BRAF mutations in Cushing's disease.
- reference: PMID:34687601
  title: 'Consensus on diagnosis and management of Cushing''s disease: a guideline update.'
- reference: PMID:34415482
  title: 'Surgical outcome of transsphenoidal surgery in Cushing''s disease: a case series of 1106 patients
    from a single center over 30 years.'
- reference: PMID:32730798
  title: 'Efficacy and safety of osilodrostat in patients with Cushing''s disease (LINC 3): a multicentre phase
    III study with a double-blind, randomised withdrawal phase.'
- reference: PMID:26156970
  title: 'Cushing''s syndrome: update on signs, symptoms and biochemical screening.'
- reference: PMID:40392165
  title: 'Prevalence and clinical associations of USP8 variants in corticotroph tumours: a systematic review
    and aggregate data meta-analysis of 2171 cases.'
- reference: PMID:30715394
  title: 'Overall and Disease-Specific Mortality in Patients With Cushing Disease: A Swedish Nationwide Study.'
- reference: PMID:39182834
  title: 'Venous Thromboembolism and Prevention Strategies in Patients with Cushing''s Disease: A Systematic
    Review.'
- reference: PMID:28505327
  title: Histone Deacetylase Inhibitor SAHA Is a Promising Treatment of Cushing Disease.
- reference: PMID:30799512
  title: 'The incidence of Cushing''s disease: a nationwide Swedish study.'
- reference: PMID:31465533
  title: 'Long-term efficacy and safety of once-monthly pasireotide in Cushing''s disease: A Phase III extension
    study.'
- reference: PMID:35325149
  title: Randomized Trial of Osilodrostat for the Treatment of Cushing Disease.
- reference: PMID:40257708
  title: 'The prevalence and predictors of Cushing disease recurrence: a 10-year experience of a pituitary
    tumor center of excellence.'
- reference: PMID:42572239
  title: 'Clinical Profile, Biochemical Characteristics, and Surgical Outcomes in Cushing Disease: An Age-Stratified
    Analysis of a Large Tertiary-Care Cohort.'
notes: 'Scope: this entry covers pituitary-dependent Cushing disease specifically. The umbrella entry Cushings_Syndrome
  covers hypercortisolism from all causes, including adrenal, ectopic-ACTH and exogenous glucocorticoid, and
  remains the right place for material that is not specific to the corticotroph adenoma. USP8-related_pituitary_adenoma_4
  is a gene-level entry without a disease_term and is not the same scope as this one.

  Granularity: the corticotroph adenoma is a benign, WHO-defined PitNET with a single settled identity, so
  the cancer granularity ladder in design decisions section 3a does not really engage here. The three molecular
  subgroups are recorded as has_subtypes rather than promoted to separate entries because none has a distinct
  first-line therapy or diagnostic pathway today - which is precisely what the knowledge-gap discussion is
  about.


  Deep research. Curated with a single OpenScientist deep-research report (research/Cushing_Disease-deep-research-openscientist.md).
  Its reference validation reported 46/46 citations verified. Its term validation reported needs_review with
  two mislabelled terms, the important one being MONDO:0005479 offered as "Cushing disease" when that CURIE
  is in fact atrial tachycardia; this entry uses MONDO:0009050. The report is what added the mortality burden,
  the perioperative VTE risk, the USP8 meta-analysis, and the AtT-20 model, and it materially corrected the
  knowledge-gap discussion: USP8 status does have a measured association with both remission and recurrence,
  which the first draft of this entry stated had not been shown.'
biochemical:
- name: Early postoperative nadir serum cortisol
  evidence:
  - reference: PMID:40257708
    reference_title: 'The prevalence and predictors of Cushing disease recurrence: a 10-year experience of
      a pituitary tumor center of excellence.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Nadir cortisol concentrations ≤3 mcg/dL during the first post-operative week predicted long-term
      remission with 74% sensitivity, 85% specificity, 94% positive predictive value, and 50% negative predictive
      value (area under the curve 0.808, p = 0.001).
    explanation: The full operating characteristics, including the asymmetry between positive and negative
      predictive value that this entry flags.
  notes: Measured during the first week after transsphenoidal surgery, this is the practical predictor of durable
    remission. A nadir at or below 3 mcg/dL predicts long-term remission with 94% positive predictive value
    - but only 50% negative predictive value, so a low nadir is reassuring while a higher one is not by itself
    a verdict.
clinical_trials:
- name: NCT02180217
  phase: PHASE_III
  status: COMPLETED
  description: LINC 3. Open-label osilodrostat titration followed by a double-blind randomised withdrawal period
    - the design that isolates the drug effect from spontaneous fluctuation in a disease with variable cortisol
    output.
  target_phenotypes:
  - preferred_term: Increased circulating cortisol level
    term:
      id: HP:0003118
      label: Increased circulating cortisol level
  evidence:
  - reference: clinicaltrials:NCT02180217
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: It was a pivotal trial which supported the registration of LCI699 for the treatment of patients
      with Cushing's disease in the US and the EU.
    explanation: The registration trial for osilodrostat, whose published results this entry cites as PMID:32730798.
- name: NCT02697734
  phase: PHASE_III
  status: COMPLETED
  description: LINC 4. Placebo-controlled from the outset for 12 weeks, then open-label to 48 weeks - the design
    that answers the objection that LINC 3's withdrawal structure could inflate the apparent effect.
  target_phenotypes:
  - preferred_term: Increased circulating cortisol level
    term:
      id: HP:0003118
      label: Increased circulating cortisol level
  evidence:
  - reference: clinicaltrials:NCT02697734
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The purpose of this study was to confirm efficacy and safety of osilodrostat for the treatment
      of patients with Cushing's disease who are candidates for medical therapy.
    explanation: The registered objective of LINC 4, whose published results this entry cites as PMID:35325149.
- name: NCT01374906
  phase: PHASE_III
  status: COMPLETED
  description: The long-acting pasireotide Phase III study and its open-label extension, which supplies this
    entry's pasireotide efficacy and hyperglycaemia figures.
  target_phenotypes:
  - preferred_term: Increased circulating ACTH level
    term:
      id: HP:0003154
      label: Increased circulating ACTH level
  evidence:
  - reference: clinicaltrials:NCT01374906
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This is a randomized, double-blind, multicenter, phase III study to evaluate the safety and efficacy
      of 2 dosing regiments of Pasireotide long acting release (LAR) in patients with Cushing's disease.
    explanation: The registered design of the long-acting pasireotide trial whose extension results this entry
      cites as PMID:31465533.
📚

References & Deep Research

References

16
PMID:25485838
Mutations in the deubiquitinase gene USP8 cause Cushing's disease.
No top-level findings curated for this source.
PMID:25675982
Recurrent gain-of-function USP8 mutations in Cushing's disease.
No top-level findings curated for this source.
PMID:30093687
Identification of recurrent USP48 and BRAF mutations in Cushing's disease.
No top-level findings curated for this source.
PMID:34687601
Consensus on diagnosis and management of Cushing's disease: a guideline update.
No top-level findings curated for this source.
PMID:34415482
Surgical outcome of transsphenoidal surgery in Cushing's disease: a case series of 1106 patients from a single center over 30 years.
No top-level findings curated for this source.
PMID:32730798
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
No top-level findings curated for this source.
PMID:26156970
Cushing's syndrome: update on signs, symptoms and biochemical screening.
No top-level findings curated for this source.
PMID:40392165
Prevalence and clinical associations of USP8 variants in corticotroph tumours: a systematic review and aggregate data meta-analysis of 2171 cases.
No top-level findings curated for this source.
PMID:30715394
Overall and Disease-Specific Mortality in Patients With Cushing Disease: A Swedish Nationwide Study.
No top-level findings curated for this source.
PMID:39182834
Venous Thromboembolism and Prevention Strategies in Patients with Cushing's Disease: A Systematic Review.
No top-level findings curated for this source.
PMID:28505327
Histone Deacetylase Inhibitor SAHA Is a Promising Treatment of Cushing Disease.
No top-level findings curated for this source.
PMID:30799512
The incidence of Cushing's disease: a nationwide Swedish study.
No top-level findings curated for this source.
PMID:31465533
Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.
No top-level findings curated for this source.
PMID:35325149
Randomized Trial of Osilodrostat for the Treatment of Cushing Disease.
No top-level findings curated for this source.
PMID:40257708
The prevalence and predictors of Cushing disease recurrence: a 10-year experience of a pituitary tumor center of excellence.
No top-level findings curated for this source.
PMID:42572239
Clinical Profile, Biochemical Characteristics, and Surgical Outcomes in Cushing Disease: An Age-Stratified Analysis of a Large Tertiary-Care Cohort.
No top-level findings curated for this source.

Deep Research

1
OpenScientist ▸
Cushing Disease: A Comprehensive Disease-Characteristics Report
openscientist-autonomous 45 citations 2026-08-28T21:50:01.796148

Cushing Disease: A Comprehensive Disease-Characteristics Report

Disease Category: Endocrine Disorder Suggested MONDO term: MONDO:0005479 (Cushing disease) — ACTH-secreting pituitary corticotroph adenoma Report basis: 16 confirmed findings across 5 investigation iterations, 70 papers reviewed.

Summary

Cushing disease (CD) is a rare, life-threatening endocrine disorder caused by a benign adrenocorticotropic hormone (ACTH)-secreting pituitary corticotroph adenoma (a pituitary neuroendocrine tumor, PitNET, of the TPIT/TBX19 lineage). Autonomous ACTH hypersecretion drives bilateral adrenal cortisol overproduction and chronic endogenous hypercortisolism, producing a characteristic multisystem "cushingoid" phenotype. CD is the most common cause of endogenous Cushing syndrome (CS), accounting for roughly 48% of cases, with a nationwide incidence of approximately 1.6 cases per million per year and a marked female predominance (~3:1). At the molecular level, the disease is most commonly driven by somatic gain-of-function mutations in USP8 (~31% of corticotroph tumors), with additional recurrent drivers in USP48 and BRAF converging on enhanced pro-opiomelanocortin (POMC) transcription and ACTH secretion; aggressive tumors are enriched for TP53 and ATRX alterations. A central pathophysiological feature is partial resistance to glucocorticoid negative feedback, which is exploited diagnostically in the dexamethasone suppression test.

The clinical burden of CD is severe. Chronic cortisol excess produces weight gain, centripetal obesity, proximal myopathy, hypertension (~80%), diabetes, osteoporosis, neuropsychiatric disturbance, reproductive dysfunction, and a hypercoagulable state that predisposes to venous thromboembolism. Untreated or persistent disease carries a 2- to 9-fold excess mortality, driven principally by cardiovascular disease and infection. Even after biochemical remission, mortality risk, quality of life, and socioeconomic function may not fully normalize, underscoring the disease's lasting impact.

First-line treatment is transsphenoidal adenomectomy, which achieves initial remission in ~80% of patients but is complicated by recurrence in ~15–27%. Medical therapies — the 11β-hydroxylase inhibitor osilodrostat, the pituitary-directed somatostatin analog pasireotide, cabergoline, metyrapone, ketoconazole/levoketoconazole, and the glucocorticoid-receptor antagonist mifepristone — plus radiotherapy and bilateral adrenalectomy are used for persistent or recurrent disease. CD occurs naturally in dogs (pituitary-dependent hyperadrenocorticism), the leading spontaneous animal model, and is studied in vitro chiefly using the murine AtT-20 corticotroph tumor cell line.

1. Disease Information

Overview. Cushing disease is defined as ACTH-dependent endogenous hypercortisolism caused specifically by a pituitary corticotroph adenoma. It is distinguished from the broader term Cushing syndrome (any cause of chronic glucocorticoid excess, including exogenous steroids, adrenal tumors, and ectopic ACTH secretion). CD is the single most common cause of endogenous CS.

Key identifiers (suggested): - MONDO: MONDO:0005479 (Cushing disease) - OMIM: 219090 (Cushing disease / pituitary ACTH-secreting adenoma phenotype); USP8 somatic association - Orphanet: ORPHA:96253 (Cushing disease) - ICD-10: E24.0 (Pituitary-dependent Cushing disease); ICD-11: 5A70 (Cushing syndrome, pituitary-dependent subgrouping) - MeSH: D047748 "Pituitary ACTH Hypersecretion"

Synonyms / alternative names: Pituitary-dependent Cushing syndrome; pituitary-dependent hypercortisolism; ACTH-secreting pituitary adenoma; corticotropinoma; Cushing disease of the pituitary; pituitary-dependent hyperadrenocorticism (veterinary term).

Source of information. This report is derived from aggregated disease-level resources — nationwide registry studies (Sweden, Denmark), tertiary-referral cohorts, systematic reviews/meta-analyses, and Phase III clinical trials — rather than from individual EHR-level patient records.

2. Etiology

Primary causal factor. CD is caused by a monoclonal, usually benign, ACTH-secreting pituitary corticotroph adenoma. The dominant molecular etiology is somatic (tumor-restricted) gain-of-function mutation, not germline inheritance in most cases.

Genetic risk / causal factors (somatic). - USP8 (ubiquitin-specific peptidase 8): the most common driver, present in ~31% of corticotroph tumors (pooled prevalence 31.1%, 95% CI 26.5–36.0%; PMID: 40392165). Hotspot variants cluster in exon 14 (14-3-3 binding motif, codons 713–720; e.g., p.Ser718Pro, p.Pro720Arg). - USP48 and BRAF — additional recurrent drivers converging on POMC/ACTH (PMID: 42236012). - TP53 and ATRX/DAXX — enriched in aggressive/silent corticotroph tumors and Crooke cell adenomas (PMID: 42273717; PMID: 41047423).

Germline predisposition (minority). Rare familial/syndromic forms involve germline variants in MEN1 (MEN1), AIP (familial isolated pituitary adenoma), CDKN1B (MEN4), PRKAR1A (Carney complex), and CDKN2A (reported in pediatric CD; PMID: 40813536). Germline genetic testing is recommended in young/pediatric patients.

Environmental risk factors. No established environmental, toxic, occupational, or infectious cause. The strongest demographic risk factors are female sex and age (peak 3rd–5th decade). USP8-mutant tumors show strong female predominance (OR 4.52; PMID: 40392165).

Protective factors / gene-environment interactions. No validated genetic or environmental protective factors are documented. Because the disease is driven by somatic mutation, classic gene-environment interaction models do not apply. Not applicable / not available for most subcategories.

3. Phenotypes

Cushing disease produces a highly prevalent, characteristic set of physical manifestations, clinical signs, and laboratory abnormalities. Frequencies below are from a large tertiary cohort (n=277; PMID: 42572239) and a hypertension-focused review (PMID: 31164868).

Phenotype Frequency Type Suggested HPO term
Weight gain 79.4% Physical manifestation HP:0004324 (Increased body weight)
Centripetal (truncal) obesity 62.5% Physical manifestation HP:0001956 (Truncal obesity)
Hyperpigmentation 61.0% Clinical sign HP:0000953 (Hyperpigmentation of the skin)
Proximal myopathy 60.6% Clinical sign HP:0003701 (Proximal muscle weakness)
Hypertension ~80% Clinical sign / lab HP:0000822 (Hypertension)
Hyperglycemia / diabetes common Laboratory abnormality HP:0003074 (Hyperglycemia)
Striae common (younger) Physical manifestation HP:0001065 (Striae distensae)
Menstrual irregularity / reproductive dysfunction highly prevalent Clinical sign HP:0000858 (Secondary amenorrhea)
Osteoporosis / fractures common Physical manifestation HP:0000939 (Osteoporosis)
Neuropsychiatric change (depression, cognitive) common Behavioral HP:0000716 (Depression)
Hypercortisolemia universal Laboratory abnormality HP:0003118 (Abnormal circulating cortisol)

Characteristics. Onset is typically adult (3rd–4th decades), insidious/chronic in progression. Severity is variable and tied to duration and intensity of cortisol excess. Age-stratified presentation: younger patients more often show striae, acne, and menstrual irregularities; older patients show more cardiometabolic comorbidity (PMID: 42572239).

"The cohort demonstrated a marked female predominance (71.8%)... Classical cushingoid features were highly prevalent, including weight gain (79.4%), centripetal obesity (62.5%), hyperpigmentation (61.0%), and proximal myopathy (60.6%)." — PMID: 42572239

Quality of life impact. CD causes lasting QoL and socioeconomic impairment that persists years after surgical cure. In a Danish nationwide cohort, employment was permanently reduced (RR 0.66 at 10 years post-surgery), with elevated sick leave (RR 2.15) and disability pension (RR 2.60) a decade after treatment (PMID: 35311897).

4. Genetic / Molecular Information

Causal genes (somatic driver landscape).

Gene (HGNC) Frequency in CD Variant type Consequence Clinical correlate
USP8 ~31% (up to 48–50% some cohorts) Missense, in-frame; exon 14 hotspots (codons 713–720) Gain-of-function; disrupts 14-3-3 binding → constitutive deubiquitinase activity Female, younger, higher remission but higher recurrence
USP48 recurrent (minority) Missense Enhanced POMC transcription Favorable/low-CNV tumors
BRAF rare V600E MAPK activation → POMC Occasional aggressive
TP53 aggressive subset Missense/LoF Loss of tumor suppression High CNV, invasion, silent/Crooke cell
ATRX/DAXX aggressive subset LoF Chromatin/telomere instability Aggressive behavior

USP8 mechanism (causal chain). Exon-14 hotspot mutations disrupt the 14-3-3 protein binding motif → constitutive USP8 activation → reduced ubiquitination and degradation of EGFR → sustained EGFR signaling → increased POMC transcription and ACTH secretion.

"Activating mutation in Ubiquitin-specific peptidase (USP8) is identified to enhance cell proliferation and adrenocorticotropic hormone (ACTH) secretion from corticotroph pituitary adenoma." — PMID: 38862897

Two divergent molecular pathways (PMID: 42273717): (1) USP8/USP48-mutant tumors — low copy-number variation (CNV), minimal invasion, favorable remission (10/21 CD tumors, 48%); (2) TP53/ATRX/DAXX-mutant tumors — high CNV, aggressive, more often clinically silent.

"USP8/USP48 mutations were present in 10 of 21 CD tumors (48%) and were associated with low CNV levels, minimal invasion, and favorable post-operative remission. In contrast, five of 13 SCAs harbored TP53/ATRX/DAXX mutations, all had markedly elevated CNV, and aggressive clinical features." — PMID: 42273717

Somatic vs germline. Overwhelmingly somatic (tumor-restricted). Germline variants (MEN1, AIP, CDKN1B, PRKAR1A, CDKN2A) account for a minority, particularly pediatric/familial cases.

Allele frequency. As somatic driver mutations, USP8 hotspot variants are absent from population germline databases (gnomAD); they are tumor-specific and catalogued in COSMIC.

Modifier genes / epigenetics / chromosomal abnormalities. Aggressive tumors show elevated CNV burden and ATRX-linked chromatin instability. Detailed methylation atlases are still emerging; not fully characterized.

5. Environmental Information

  • Environmental factors: None established. CD is not linked to documented toxin, radiation, or pollution exposures.
  • Lifestyle factors: No causal lifestyle factor identified; obesity and metabolic features are consequences rather than causes.
  • Infectious agents: Not applicable — CD has no infectious etiology.

This section is largely not applicable for Cushing disease, consistent with a somatically-driven neoplastic endocrine disorder.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream):

Somatic driver mutation (USP8 / USP48 / BRAF)
│  (constitutive deubiquitinase / MAPK activation)
▼
Sustained EGFR signaling → ↑ POMC transcription (TPIT/TBX19 lineage)
│
▼
Autonomous ACTH hypersecretion  ← PARTIAL glucocorticoid feedback resistance (GR/NR3C1)
│
▼
Bilateral adrenal stimulation → chronic cortisol excess (hypercortisolism)
│
├──► Mineralocorticoid receptor activation (11β-HSD2 saturation) → HYPERTENSION
├──► Insulin resistance / gluconeogenesis → DIABETES, visceral adiposity
├──► Protein catabolism → MYOPATHY, osteoporosis, thin skin/striae
├──► Procoagulant shift → VENOUS THROMBOEMBOLISM
├──► HPG axis suppression → reproductive/sexual dysfunction
└──► CNS effects → depression, cognitive impairment

Molecular pathways. EGFR signaling (via USP8-mediated stabilization), MAPK (BRAF), and ubiquitin–proteasome deubiquitination converge on POMC transcription. Suggested GO terms: GO:0030518 (intracellular receptor signaling), GO:0016579 (protein deubiquitination), GO:0007173 (EGFR signaling), GO:0042446 (hormone biosynthetic process).

Glucocorticoid-feedback resistance. The glucocorticoid receptor (GR/NR3C1) is the principal mediator of HPA-axis negative feedback; CD tumors show partial resistance, which underlies the diagnostic dexamethasone suppression test.

"CD patients exhibit a partial resistance to the negative glucocorticoid (GC) feedback, which is of paramount clinical utility, as the lack of suppression after dexamethasone administration is one of the mainstays for the differential diagnosis of CD." — PMID: 35742910

Hypertension mechanism. Cortisol excess saturates renal 11β-HSD2, permitting cortisol to activate the mineralocorticoid receptor (mineralocorticoid mimetic activity), alongside altered vascular resistance and vascular remodeling.

"Glucocorticoid excess leads to hypertension via a variety of mechanisms including mineralocorticoid mimetic activity, alterations in peripheral and renovascular resistance, and vascular remodeling." — PMID: 31164868

Single-cell / spatial biology. snRNA-seq (419,874 cells) plus spatial transcriptomics show corticotroph adenomas exist along a transcriptional continuum with developmental plasticity, and that perivascular niches enhance tumorigenicity via angiogenic and EMT programs (PMID: 40666832). scRNA-seq identified a novel GZMK-high TPIT-lineage subpopulation and validated PBK as an aggressiveness driver (PMID: 38167466); alternative-splicing analysis defined an ESRP1-driven aggressive TPIT subtype (PMID: 39934142).

Cell types (suggested CL terms): corticotroph / ACTH-secreting cell (corticotropic cell of pars distalis), adrenal cortical cell (CL:0002097). Subcellular: nucleus (GO:0005634), secretory granules (GO:0030141), endoplasmic reticulum (ER stress implicated via PCSK1N; PMID: 39288010).

7. Anatomical Structures Affected

Primary organ: Anterior pituitary gland (adenohypophysis) — UBERON:0000007 (pituitary gland); specifically corticotroph cells of the pars distalis.

Secondary organs (via cortisol excess): Adrenal cortex (bilateral hyperstimulation; UBERON:0001235), cardiovascular system (UBERON:0004535), skeletal muscle (UBERON:0001134), bone/skeleton (UBERON:0002481), skin (UBERON:0002097), liver (metabolic; hepatic hemangioma association reported, PMID: 42332692), gonads/HPG axis, and central nervous system.

Body systems involved: Endocrine (primary), cardiovascular, musculoskeletal, integumentary, reproductive, nervous/psychiatric, hematologic (hypercoagulability), and immune (infection susceptibility).

Tissue/cell level: Neuroendocrine epithelial (corticotroph) tumor tissue; adrenal cortical zona fasciculata; vascular endothelium (remodeling); adipose tissue (redistribution).

Localization / lateralization: The pituitary microadenoma is usually a small (<10 mm) intrasellar lesion; adrenal effects are bilateral and symmetric (diffuse hyperplasia). MRI localization of the corticotroph microadenoma is notoriously reader-dependent, and ~10% of cases are MRI-negative (PMID: 42537231; PMID: 42517988).

8. Temporal Development

  • Onset: Adult-onset typical (peak 3rd–5th decade); pediatric and geriatric cases occur. Pattern is insidious/chronic, often with diagnostic delay of months to years.
  • Progression: Slowly progressive if untreated; cortisol excess drives cumulative cardiometabolic, skeletal, and vascular damage. Rare cyclic/episodic hypercortisolism complicates diagnosis.
  • Disease course pattern: Chronic; treatment-induced remission is the goal. Recurrence occurs in ~15–27% after surgery (median ~38 months; PMID: 40257708), so the course can be relapsing.
  • Lifespan variation: Presentation differs across age — growth arrest with weight gain in children; pubertal/psychological disturbance in adolescents; classic cushingoid features in adults; frailty, sarcopenia, fractures, and cognitive decline in the elderly (PMID: 42095775).

"In children, impaired growth coupled with weight gain is most prominent, whereas adolescents often present with pubertal disturbances and psychological or academic difficulties." — PMID: 42095775

  • Critical periods: Early biochemical control is the key window to prevent irreversible cardiovascular and skeletal damage.

9. Inheritance and Population

Epidemiology. - Incidence: ~1.6 cases per million per year (Sweden nationwide; rising to ~2.0/million in 2005–2013) (PMID: 30799512). - Endogenous CS incidence: 1.8–3.2 per million/year (PMID: 33766428); CD comprises ~48% of endogenous CS (~1.5/million/yr) (PMID: 31094003).

"The incidence of CD in Sweden (1.6 cases per million)." — PMID: 30799512

Inheritance. Predominantly sporadic/somatic (not inherited). A minority are syndromic (MEN1, MEN4, Carney complex, FIPA) with autosomal dominant inheritance and incomplete, age-dependent penetrance.

Demographics. - Sex ratio: Female predominance ~3:1; USP8-mutant tumors are almost exclusively female (OR 4.52). - Age distribution: Peak onset 3rd–5th decade. - Race/ethnicity differences: Black patients present younger, higher BMI, near-uniformly solid tumors, higher radiographic persistence (38% vs 21%) and reintervention (25% vs 4.5%); Hispanic patients present with milder disease; durable remission comparable across groups (79–88%) (PMID: 42560567).

"Black patients were younger (p = 0.003), with higher BMI (p = 0.033) and near-uniformly solid tumors (94%; p = 0.040)." — PMID: 42560567

10. Diagnostics

Screening / first-line biochemical tests (Endocrine Society approach; PMID: 28069628): - 24-hour urinary free cortisol (UFC) - Late-night salivary cortisol - Overnight 1-mg dexamethasone suppression test (DST) / low-dose 48-hour DST

Confirming ACTH-dependence and source: - Plasma ACTH (elevated/inappropriately normal → ACTH-dependent) - High-dose DST; CRH stimulation test - Bilateral inferior petrosal sinus sampling (BIPSS) — gold standard to distinguish pituitary from ectopic ACTH source

Imaging: Pituitary MRI (dynamic/3D spoiled gradient echo improves microadenoma detection), but localization is strongly reader-dependent with fair-to-moderate interrater agreement (κ = 0.34–0.44); consensus interpretation improves performance (PMID: 42537231). ~10% are MRI-negative, raising the risk of misdiagnosed ectopic ACTH tumors (PMID: 42517988).

Pathology / IHC: ACTH-positive, TPIT/TBX19-positive corticotroph adenoma; Crooke cell change indicates aggressive subtype.

Genetic testing: Somatic tumor sequencing (USP8, USP48, BRAF, TP53) for prognostication; germline panels (MEN1, AIP, CDKN1B, PRKAR1A, CDKN2A) recommended in pediatric/young patients (PMID: 40813536).

Differential diagnosis: Ectopic ACTH syndrome, adrenal Cushing (ACTH-independent), pseudo-Cushing states, and mild autonomous cortisol secretion (MACS).

11. Outcome / Prognosis

Mortality. CD carries a 2- to 9-fold excess mortality, driven principally by cardiovascular disease and infection.

Cohort SMR Key detail Source
Swedish nationwide (n=502) 2.5 (95% CI 2.1–2.9) CVD leading cause (SMR 3.3); remission SMR still 1.9 PMID: 30715394
Oxford/Athens (n=311 CD) 9.3 (95% CI 6.2–13.4) 10-yr survival 95.3%; 71.4% deaths CV/infection PMID: 23996696
Italian 20-yr (n=126) Persistent 4.99; remission 1.66 (NS) Remission status is key determinant PMID: 37495935

"The observed number of deaths was 133 vs 54 expected, resulting in an overall SMR of 2.5... The commonest cause of death was cardiovascular diseases (SMR, 3.3)." — PMID: 30715394

Morbidity & complications: Hypertension, diabetes, osteoporosis/fractures, venous thromboembolism, infections/sepsis, neuropsychiatric disease, reproductive dysfunction, and (reported) hepatic hemangioma. Venous thromboembolism is a key preventable complication: pooled post-operative VTE incidence 2% (58/2997) with VTE-associated mortality 0.2% (PMID: 39182834).

"Pooled postoperative VTE incidence in patients undergoing transsphenoidal surgery for CD was 2% (58 out of 2997)." — PMID: 39182834

Prognostic factors: Remission status is the strongest determinant of long-term survival. Post-operative nadir cortisol ≤3 µg/dL predicts durable remission (AUC 0.808); macroadenomas and USP8-mutant status predict higher recurrence (PMID: 40257708; PMID: 40424186).

Quality of life: Persistently impaired years after cure (PMID: 35311897).

12. Treatment

First-line: Transsphenoidal surgery (TSS) — adenomectomy. Initial remission ~81%, recurrence ~27.4% (median 38 months); nadir cortisol ≤3 µg/dL and microadenoma status predict durable remission (NCIT: Transsphenoidal Hypophysectomy).

"Surgical remission was achieved in 81% of patients, but recurrence occurred in 27.4% of cases after a median follow up period of 38 months." — PMID: 40257708

Pharmacotherapy (for persistent/recurrent/inoperable disease):

Drug Class / mechanism (NCIT) Efficacy Key toxicity Source
Osilodrostat 11β-hydroxylase (CYP11B1) inhibitor 77% vs 8% placebo achieved mUFC ≤ULN at wk 12; 81% at wk 36; median time to control 35 days Adrenal insufficiency, nausea, hypocortisolism, tumor enlargement PMID: 35325149; PMID: 32730798; PMID: 41052284
Pasireotide Pituitary-directed SSTR5 somatostatin analog ~50–53% mUFC control Hyperglycemia (39.5%), nausea, cholelithiasis PMID: 37876540; PMID: 31465533
Cabergoline Dopamine agonist (D2) Adjunct, variable Generally well tolerated PMID: 37876540
Metyrapone / Ketoconazole / Levoketoconazole Steroidogenesis inhibitors Effective cortisol lowering Hepatotoxicity (keto), adrenal insufficiency PMID: 26133755
Mifepristone Glucocorticoid receptor antagonist Controls hypercortisolism effects Hypokalemia, endometrial effects PMID: 42533758

"At week 12, significantly more osilodrostat (77%) than placebo (8%) patients achieved mUFC ≤ ULN (odds ratio 43.4; 95% CI 7.1, 343.2; P < 0.0001)." — PMID: 35325149

"Thirty-four patients (50.0%; 95% CI 37.6-62.4) achieved the primary endpoint." (pasireotide ± cabergoline) — PMID: 37876540

Second-line / other: Pituitary radiotherapy (conventional or stereotactic; slow onset), repeat TSS, and bilateral adrenalectomy (definitive cortisol control but requires lifelong replacement and risks Nelson syndrome). Drug treatment is frequently discontinued long-term (only 38% of one cohort remained on it as final treatment; PMID: 37962981).

Supportive care: Antihypertensives, glycemic control, osteoporosis management, and VTE prophylaxis — routine rivaroxaban (10 mg/day) was safe with no major/minor bleeding in ACTH-dependent CS (PMID: 41540719).

Pharmacogenomics / personalized medicine: USP8 status may guide expectations for recurrence; Asian patients require lower osilodrostat doses and show more hypocortisolism-related AEs than non-Asian patients (PMID: 39183039).

13. Prevention

Because CD arises from sporadic somatic mutation, primary prevention is not applicable — there is no known modifiable risk factor or vaccine.

  • Secondary prevention (early detection): Targeted case-finding using the overnight 1-mg DST in high-risk groups (resistant type 2 diabetes, resistant hypertension, adrenal incidentalomas) can uncover treatable hypercortisolism (PMID: 42591054; PMID: 42533758). Population-wide screening is not recommended.
  • Tertiary prevention (complication prevention): Aggressive control of hypertension, hyperglycemia, osteoporosis, and thromboprophylaxis; close post-surgical surveillance for recurrence.
  • Genetic counseling: Indicated for syndromic/pediatric cases with germline predisposition (MEN1, Carney complex, FIPA).

14. Other Species / Natural Disease

Cushing disease occurs naturally in dogs as pituitary-dependent hyperadrenocorticism (PDH) — the leading spontaneous animal model, comprising ~80–85% of canine Cushing's.

"Hypercortisolism is well defined in dogs, with well established and extensively documented clinical signs, various diagnostic methods and treatment options available." — PMID: 42440375

  • Taxonomy: Canis lupus familiaris (NCBI Taxon 9615); also reported in guinea pigs, Cavia porcellus (NCBI Taxon 10141).
  • Natural disease: Canine PDH features defined clinical signs, validated diagnostics (low-dose dexamethasone suppression, urinary corticoid:creatinine ratio, endogenous ACTH), and medical therapy with trilostane (3β-HSD/steroidogenesis inhibitor). A naturally occurring ACTH-dependent pituitary blastoma (TBX19/TPIT+, ACTH+) was documented in a dog (PMID: 42177605).
  • Comparative biology: Corticotroph lineage markers (TPIT/TBX19) and ACTH-driven pathophysiology are conserved between dogs and humans, supporting cross-species mechanistic relevance.
  • Zoonotic potential: Not applicable (non-communicable).

15. Model Organisms

Principal in vitro model: AtT-20 — the murine (mouse) pituitary corticotroph adenoma cell line, the standard preclinical model for ACTH-secreting tumors, used both in culture and as nude-mouse xenografts.

  • HDAC inhibitor SAHA (vorinostat) reduces POMC transcription and ACTH secretion in human and murine (AtT-20) cells and suppresses xenograft growth (PMID: 28505327).
  • Romidepsin (HDAC1/2 inhibitor) suppresses ACTH via PTTG1 downregulation in AtT-20 cells (PMID: 33181265).
  • Additional AtT-20 mechanistic studies implicate ER stress / PCSK1N (PMID: 39288010) and FAF1 (PMID: 38065537).

Model types: Cellular/in vitro (AtT-20; human primary corticotroph cultures), murine xenografts, and spontaneous canine disease (natural model). Limitations: AtT-20 cells do not carry the human USP8 hotspot mutation; no widely-used genetically engineered mouse recapitulates human USP8-driven CD, limiting fidelity of driver-mechanism modeling. Resources: MGI (mouse), Cellosaurus (AtT-20).

Mechanistic Model / Interpretation

Cushing disease is best understood as a two-tier disorder: (1) a corticotroph tumor tier, in which somatic driver mutations — chiefly USP8, with USP48 and BRAF — converge on enhanced POMC/ACTH output, while a divergent aggressive subset defined by TP53/ATRX/DAXX drives invasion and silent phenotypes; and (2) a systemic hypercortisolism tier, in which autonomous ACTH escapes partial glucocorticoid feedback, chronically stimulates the adrenal cortex, and produces cortisol-mediated end-organ damage across cardiovascular, metabolic, skeletal, hematologic, reproductive, and neuropsychiatric systems.

The unifying diagnostic and therapeutic logic follows directly from this model: (a) feedback resistance underlies the dexamethasone suppression test; (b) ACTH-dependence localizes the lesion via BIPSS; (c) the tumor tier is addressed by surgery/radiotherapy/pituitary-directed pasireotide, while the hypercortisolism tier is addressed by steroidogenesis inhibitors (osilodrostat, metyrapone, ketoconazole), GR blockade (mifepristone), or bilateral adrenalectomy. Because cortisol-driven cardiovascular and thrombotic damage accumulates over time and does not fully reverse, early biochemical control is the dominant prognostic lever — remission converts a 5–9× mortality risk toward (though not fully to) baseline.

GENOTYPE                PHENOTYPE                      OUTCOME
USP8/USP48/BRAF  ──►  ↑POMC/ACTH ──► cortisol ──►  cushingoid multisystem disease
(favorable)          (feedback-resistant)          │
                                            ├─ treated/remission → SMR ~1.7–1.9
TP53/ATRX/DAXX   ──►  aggressive/silent tumor       └─ persistent → SMR ~5–9 (CVD, infection)
(aggressive)

Evidence Base

PMID Contribution Type
40392165 USP8 prevalence meta-analysis (31.1%), clinical associations Meta-analysis
38862897 USP8 gain-of-function → ACTH secretion mechanism Review/experimental
42273717 Two divergent molecular pathways (USP8/USP48 vs TP53/ATRX) WES/CNV/transcriptome
42236012 Recurrent driver convergence on POMC/ACTH Molecular review
35742910 Glucocorticoid-feedback resistance as core pathophysiology Review
31164868 Hypertension mechanism (mineralocorticoid mimicry) Review
30715394 Nationwide SMR 2.5, CVD leading cause Registry cohort
37495935 Remission status determines mortality 20-yr cohort
40257708 Surgical remission 81%, recurrence 27.4% Tertiary cohort
40424186 USP8 predicts recurrence Cohort
35325149 Osilodrostat Phase III (LINC 4) efficacy RCT
37876540 / 31465533 Pasireotide efficacy (~50%) and hyperglycemia Phase II/III
39182834 / 41540719 VTE burden and prophylaxis Systematic review / cohort
42572239 Phenotype frequencies, demographics Tertiary cohort
35311897 Persistent socioeconomic/QoL impairment Nationwide cohort
30799512 / 31094003 / 33766428 Incidence (~1.6/million; CD ~48% of CS) Registry/epidemiology
40666832 / 38167466 / 39934142 Single-cell/spatial tumor heterogeneity scRNA/spatial-seq
42095775 Lifespan-varying presentation Clinical review
42560567 / 42445877 Race/ethnicity differences; HPG suppression Cohorts
42440375 / 42177605 Canine natural disease model Veterinary
28505327 / 33181265 AtT-20 preclinical model In vitro/xenograft

Limitations and Knowledge Gaps

  1. Epidemiology skew: Incidence estimates derive largely from Swedish/European registries; global and low-income-country data are sparse, and figures may underestimate mild/subclinical disease (MACS).
  2. Germline landscape under-characterized: The genetic basis of most pediatric and sporadic corticotroph tumors remains unknown beyond the somatic drivers.
  3. Epigenetics: DNA methylation/histone-modification atlases for CD are still emerging; mechanistic epigenetic drivers are not fully defined.
  4. Imaging limitation: MRI microadenoma localization is reader-dependent and ~10% MRI-negative, contributing to misdiagnosis of ectopic ACTH tumors.
  5. Model fidelity: No standard genetically engineered mouse recapitulates human USP8-driven CD; AtT-20 lacks the human hotspot mutation.
  6. Residual risk after cure: Mechanisms of persistent excess mortality and QoL impairment despite biochemical remission are incompletely understood.
  7. Metabolomics/proteomics/lipidomics signatures specific to CD were not deeply catalogued in this investigation — a genuine data gap.

Proposed Follow-up Experiments / Actions

  1. Genotype-stratified outcome registries: Prospectively link somatic driver status (USP8/USP48/BRAF/TP53) to remission, recurrence, and mortality to formalize molecular prognostication.
  2. USP8-mutant mouse model: Engineer a corticotroph-specific Usp8 hotspot knock-in to test targeted EGFR/USP8 inhibition in vivo.
  3. Residual cardiovascular risk trials: Test whether intensified cardiometabolic and thromboprophylactic management after remission normalizes the residual SMR (~1.9).
  4. Multi-omics integration: Deploy CD-specific metabolomics/lipidomics/proteomics (MetaboLights, PRIDE) to define circulating biomarkers for early detection and monitoring.
  5. Imaging enhancement: Validate consensus/AI-assisted MRI reads and molecular PET tracers to reduce MRI-negative misclassification.
  6. Targeted therapy translation: Advance EGFR-pathway and HDAC-inhibitor (SAHA/romidepsin) strategies from AtT-20/xenograft to early-phase human trials.

Consensus Answer

Cushing disease is a rare endocrine disorder (incidence ~1.6 cases/million/year; ~48% of endogenous Cushing syndrome) caused by a benign ACTH-secreting pituitary corticotroph adenoma driving chronic cortisol excess — most commonly via somatic gain-of-function USP8 mutations (~31%; also USP48, BRAF) that enhance POMC/ACTH output amid partial glucocorticoid-feedback resistance, while aggressive tumors carry TP53/ATRX alterations. It produces a multisystem cushingoid phenotype (central obesity, myopathy, hypertension, diabetes, osteoporosis, thromboembolism, neuropsychiatric and reproductive dysfunction) with 2–9× excess mortality driven chiefly by cardiovascular disease. First-line treatment is transsphenoidal adenomectomy (~80% remission, ~15–27% recurrence), with medical therapy (osilodrostat, pasireotide, cabergoline, metyrapone, ketoconazole, mifepristone), radiotherapy, and bilateral adrenalectomy for persistent or recurrent disease.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 46
Resolved 46
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 46
On topic 30
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 26
Resolved 25
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 1
Terms whose name was checked 17
Terms named correctly 12
Terms named as a different term 2
Terms whose name is worth a second look 3

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • MONDO:0005479 (2 mentions) - the report calls it "Cushing disease"; MONDO calls it atrial tachycardia
  • HP:0000858 (1 mention) - the report calls it "Secondary amenorrhea"; HP calls it Irregular menstruation

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

  • HP:0003118 (1 mention) - the report calls it "Abnormal circulating cortisol"; HP calls it Increased circulating cortisol level
  • GO:0030518 (1 mention) - the report calls it "intracellular receptor signaling"; GO calls it nuclear receptor-mediated steroid hormone signaling pathway, and lists "intracellular steroid hormone receptor signaling pathway" among its other names
  • GO:0007173 (1 mention) - the report calls it "EGFR signaling"; GO calls it epidermal growth factor receptor signaling pathway, and lists "EGFR signaling pathway" among its other names

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.